GABAergic mechanisms in epilepsy and  contribution of the ClC-2 chloride channel to neuronal excitability by Niturad, Cristina Elena
  
 
 
 
GABAergic mechanisms in epilepsy and  
contribution of the ClC-2 chloride channel to neuronal excitability 
 
 
 
 
 
Dissertation 
 
zur Erlangung des Grades eines 
Doktors der Naturwissenschaften 
 
 
der Mathematisch-Naturwissenschaftlichen Fakultät 
und 
der Medizinischen Fakultät 
der Eberhard-Karls-Universität Tübingen 
 
 
 
vorgelegt 
von 
 
Cristina Elena Niturad 
aus Fagaras, Romania 
 
 
Februar - 2016 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag der mündlichen Prüfung:  25.04.2016 
 
Dekan der Math.-Nat. Fakultät: Prof. Dr. W. Rosenstiel 
Dekan der Medizinischen Fakultät: Prof. Dr. I. B. Autenrieth 
 
1. Berichterstatter:     Prof. Dr. Holger Lerche 
2. Berichterstatter:    Dr. Maria Kukley 
 
Prüfungskommission:   Prof. Dr. Holger Lerche 
  Dr. Maria Kukley 
  Prof. Dr. Rejko Krüger 
                                     Prof. Dr. Elke Guenther
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erklärung / Declaration: 
 
Ich erkläre, dass ich die zur Promotion eingereichte Arbeit mit dem Titel:  
„GABAergic mechanisms in epilepsy and contribution of the ClC-2 chloride channel to neuronal 
excitability“  
selbständig verfasst, nur die angegebenen Quellen und Hilfsmittel benutzt und wörtlich oder 
inhaltlich übernommene Stellen als solche gekennzeichnet habe.  Ich versichere an Eides 
statt, dass diese Angaben wahr sind und dass ich nichts verschwiegen habe.  Mir ist bekannt, 
dass die falsche Abgabe einer Versicherung an Eides statt mit Freiheitsstrafe bis zu drei 
Jahren oder mit Geldstrafe bestraft wird. 
 
I hereby declare that I have produced the work entitled “GABAergic mechanisms in epilepsy 
and contribution of the ClC-2 chloride channel to neuronal excitability”, submitted for the award 
of a doctorate, on my own (without external help), have used only the sources and aids 
indicated and have marked passages included from other works, whether verbatim or in 
content, as such. I swear upon oath that these statements are true and that I have not 
concealed anything. I am aware that making a false declaration under oath is punishable by a 
term of imprisonment of up to three years or by a fine. 
 
 
 
Tübingen, den .........................................  ............................................................. 
   Datum / Date    Unterschrift /Signature
4 
 
Table of Contents 
List of abbreviations ................................................................................................................................ 6 
1 Summary.......................................................................................................................................... 8 
2 Introduction ................................................................................................................................... 10 
2.1 Epilepsy .................................................................................................................................. 10 
2.1.1 Idiopathic epilepsies ...................................................................................................... 11 
2.1.2 Epileptic encephalopathies ........................................................................................... 12 
2.2 GABAA Receptors structure and function .............................................................................. 12 
2.2.1 Dysregulation of GABAARs in epilepsy ........................................................................... 14 
2.3 GABAB receptors .................................................................................................................... 15 
2.4 ClC-2 channels ....................................................................................................................... 17 
2.4.1 The thalamo-cortical system ......................................................................................... 19 
2.5 Aims ....................................................................................................................................... 21 
3 Materials and Methods ................................................................................................................. 22 
3.1 Molecular biology .................................................................................................................. 22 
3.1.1 Vector constructs .......................................................................................................... 22 
3.1.2 Mutagenesis .................................................................................................................. 22 
3.1.3 Transformation .............................................................................................................. 24 
3.1.4 DNA purification ............................................................................................................ 24 
3.1.5 Sequencing .................................................................................................................... 24 
3.1.6 DNA linearization ........................................................................................................... 24 
3.1.7 RNA preparation ............................................................................................................ 25 
3.1.8 Genotyping .................................................................................................................... 26 
3.2 Xenopus laevis oocyte experiments ...................................................................................... 26 
3.2.1 Oocyte preparation and RNA injection ......................................................................... 26 
3.2.2 Automated oocyte two-electrode voltage clamp ......................................................... 28 
3.3 Cell culture ............................................................................................................................. 29 
3.3.1 Mouse hippocampi cell culture preparation ................................................................. 29 
3.3.2 Network activity recordings using the microelectrode arrays (MEAs).......................... 30 
3.4 Acute thalamo-cortical brain slice preparation ..................................................................... 31 
3.5 Electrophysiological techniques ............................................................................................ 32 
3.5.1 Patch-clamp method ..................................................................................................... 32 
3.5.2 Voltage clamp experiments ........................................................................................... 36 
3.5.3 Current clamp experiments ........................................................................................... 36 
3.5.4 Extracellular field recordings ......................................................................................... 37 
5 
 
3.6 Data analysis .......................................................................................................................... 38 
3.6.1 GABA-induced currents ................................................................................................. 38 
3.6.2 GIRK current analysis ..................................................................................................... 39 
3.6.3 MEA analysis .................................................................................................................. 39 
3.6.4 Electrophysiological analysis ......................................................................................... 41 
3.6.5 Statistical analysis .......................................................................................................... 43 
4 Results ........................................................................................................................................... 44 
4.1 GABRA3 mutations as a cause of X-linked epileptic encephalopathy ................................... 44 
4.2 Functional analysis of two de novo mutations identified in patients with EE in the GABBR2 
gene.... ............................................................................................................................................... 54 
4.3 ClC-2 channel and its role in neuronal excitability ................................................................ 61 
4.3.1 Cl- currents mediated by ClC-2 channels in acute thalamocortical slices ..................... 62 
4.3.2 Firing properties of inhibitory neurons in the NRT ....................................................... 63 
4.3.3 Extracellular recordings ................................................................................................. 66 
4.3.4 Network analysis using the Microelectrode array (MEA) system ................................. 67 
5 Discussion ...................................................................................................................................... 71 
5.1 Novel GABRA3 mutations as a cause of X-linked EE ............................................................. 71 
5.1.1 Loss of function mutations in GABRA3 gene and functional consequences ................. 72 
5.2 GABBR2 de novo mutations as a cause of EE ........................................................................ 74 
5.2.1 Gain of function mechanism of de novo I705N and S695I mutations ........................... 75 
5.3 ClC-2 channels and their contribution to neuronal excitability ............................................ 77 
5.3.1 ClC-2 channel and its expression in the thalamocortical system .................................. 77 
5.3.2 Less inhibition in the thalamocortical system ............................................................... 78 
5.3.3 Contribution of neurons derived from ClC-2 KO mice to the network activities .......... 79 
6 References ..................................................................................................................................... 81 
7 Acknowledgments ......................................................................................................................... 93 
 
 
 
 
 
 
6 
 
List of abbreviations 
aCSF Artificial cerebro-spinal fluid 
AP Action potential 
cAMP Cyclic adenosine monophosphate 
Cav2.1-2.2 Voltage gated calcium channels 2.1 or 2.2 
CBS Cystathionine--synthase  
cDNA Complementary deoxyribonucleic acid 
ClC Chloride channel 
CMV Cytomegalovirus  
CNV Copy number variant  
CNS  Central nervous system 
cRNA Complementary ribonucleic acid  
DEPC Diethylpyrocarbonate 
DMEM Dulbecco's Modified Eagle Medium 
dNTP Deoxyribose nucleotide triphosphates   
EC50 Half maximal effective concentration 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol tetraacetic acid 
EE Epileptic encephalopathy 
EEIE Early Infantile EE 
ER Endoplasmic reticulum  
FDS Focal dyscognitive seizures  
GABA -aminobutyric acid 
GABAA-B-CR -aminobutyric acid receptor A, B or C subtype 
GABAB1-B2 -aminobutyric acid receptor B subunit 1 or 2
GIRK G-protein inward rectifying potassium channel 
GlialCAM Glial cell adhesion molecule 
GTCS Generalized tonic-clonic seizure 
HBSS Hank's Balanced Salt Solution 
HET Heterozygous  
IBI Inter-burst interval 
ID Intellectual disability 
IGE Idiopathic generalized epilepsy 
ILAE International League Against Epilepsy 
7 
 
IS Infantile spasm 
ISI Inter-spike interval 
KCC2 Potassium-chloride cotransporter 2  
KCTD Potassium-channel tetramerization domain 
Kir Inward rectifying potassium channel 
KO Knockout  
MEA Microelectrode array 
MFR Mean firing rate 
NB Neurobasal 
NCBI National Center for Biotechnology Information 
Nav1.1 Voltage gated sodium channel 1.1 
NMDA-R N-Methyl-D-aspartic acid receptor 
NRT Nucleus reticularis of the thalamus 
PB Population burst 
PCR Polymerase chain reaction 
PFR Peak firing rate 
p/s Penicillin streptomycin 
REM Rapid eyes movement  
SEM Standard error of the mean 
SD Standard deviation 
TEVC Two-electrode voltage-clamp 
TiN Titanium nitride 
TM Transmembrane domain 
VB Ventrobasal 
WS West syndrome 
WT Wildtype  
 
 
 
 
 
 
 
 
 
 
8 
 
1 Summary 
In this thesis, I aimed to investigate the role of anion conductances for neuronal 
hyperexcitability and inherited epilepsy. I examined the functional consequences of novel 
epilepsy-causing mutations identified in GABAA or GABAB receptors. Additionally, a ClC-2 
knockout (KO) mouse model was used to investigate the ClC-2 channel contribution to 
neuronal excitability in the thalamus and hippocampus. 
In the first part, four novel mutations, identified by our collaborators in the 3 subunit 
of the GABAA receptor (gene GABRA3 on the X chromosome), were functionally characterized. 
Two mutations, Q242L and T166M, were found in two families with epileptic encephalopathy 
(EE), intellectual disability (ID), and other symptoms, as nystagmus, cleft palate and 
micrognathia. The EE phenotype followed an X-chromosomal inheritance pattern, affecting 
more severely the males, whereas females were mildly affected. Furthermore, two non-co-
segregating mutations were detected, T336M in one of two sisters affected with 
idiopathic/genetic generalized epilepsy (IGE/GGE), and G47R in one of two brothers with 
autism spectrum disorder, both inherited by their unaffected mothers. To assess the 
pathogenicity of these variants, we introduced them into the cDNA of the human GABRA3 
gene and compared their properties to the wildtype (WT) using a Xenopus laevis expression 
system. The cRNAs coding for 3 WT or mutant GABAA receptor subunits were co-injected 
with β2 and γ2 subunits and recordings were performed using automated two-electrode 
voltage-clamp recordings. A strong loss-of-function with >75% reduction in GABA-induced 
current amplitudes in comparison to the WT was found for both mutations associated with EE 
(Q242L and T166M), and the one associated with IGE (T336M). The reduction in GABA-induced 
current was much less pronounced (46.04 ± 9.46%) for G47R. The obtained results suggest 
that GABRA3 mutations with a severe loss-of-function can cause X-linked EE with dysmorphic 
features. The missing co-segregation and genotype-phenotype correlation for the IGE- and 
autism-associated mutations imply that further genetic factors are involved to cause the 
disease in these families.  
In the second part of my thesis, I have analyzed two de novo mutations found in 
GABBR2, encoding subunit 2 of the metabotropic GABAB receptor, in two unrelated patients 
with severe EE. Both patients present with profound ID and severe seizures. Functional 
analysis was also performed in Xenopus laevis oocytes. cRNAs of GABAB receptor subunits 1 
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and 2 were co-injected to form functional GABAB receptor, and Kir3.1/3.2 K+ channels were 
co-expressed as a reporter. Both mutations caused a gain of channel function manifesting at 
lower GABA concentrations. A significant increase in GABA sensitivity was found for I705N 
(EC50 of 0.48 ± 0.16 µM vs. 3.98 ± 0.68 µM for the WT) and S695I (EC50 of 0.31 ± 0.2 µM vs. 
3.96 ± 0.85 µM for the WT). Additionally, a significantly slower deactivation time constant in 
comparison with the WT, indicating a gain of function effect was observed for the S695I 
mutation. The increased sensitivity of both mutations at nanomolar GABA concentration, 
suggest a common pathomechanism based on increased activity of GABABRs at extrasynaptic 
sites. Nevertheless, for a deeper understanding of how gain of function of the GABAB receptor 
could mediate the epileptic phenotype, further functional investigations using neuronal cells 
are necessary.  
In the third part of my thesis, I worked on the contribution of ClC-2 channels to 
neuronal excitability. To this end, I analyzed neuronal activity in thalamo-cortical brain slices 
and hippocampal primary cultures obtained from WT and ClC-2 KO mice. Recordings from 
brain slices revealed that the action potential firing rate was significantly reduced in inhibitory 
neurons of the nucleus reticularis thalami (NRT) in ClC-2 KO mice in comparison with those 
from WT animals, suggesting less inhibition in the thalamocortical system and possibly 
increased excitability of the whole network. To verify this hypothesis, I recorded network 
activity using extracellular synchronous recordings in NRT, ventrobasal nucleus (VB) and 
cortex. An increase in synchronized activity in the three areas was observed in ClC-2 KO mice 
when GABAA receptors were blocked by picrotoxin, suggesting that the lack of ClC-2 may 
present a susceptibility factor for increased neuronal excitability. In addition, microelectrode 
array (MEA) recordings of hippocampal primary cultured neurons derived from KO and WT 
mice revealed that the lack of ClC-2 increases neuronal excitability by increasing the duration 
of spontaneous burst activity. Furthermore, the network properties of neurons derived from 
ClC-2 KO mice were not further altered by the GABAA receptor antagonist bicuculline in 
contrast to those of WT mice, suggesting that the loss of ClC-2 alone modulates the action of 
GABAA receptors. These results suggest that the ClC-2 channel has complex and important 
physiological functions and does play a role in the regulation of neuronal excitability. 
Altogether, my thesis shows the importance of three players of neuronal excitability 
and inhibitory function of the nervous system, revealing different roles for epileptogenic 
mutations in GABAA and GABAB receptor subunits, and loss of the ClC-2 Cl- channel. 
                                                                                                                                                              Introduction 
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2 Introduction 
2.1 Epilepsy 
Epilepsy (from ancient Greek: to seize) is a common brain disorder characterized by an 
alteration of the normal brain excitability. Approximately 50 million people worldwide are 
affected by this disease. The International League Against Epilepsy (ILAE) defined epilepsy in 
relation to the incurrence of one (or more) of the following clinical conditions: The patient has 
(1) at least two unprovoked seizures occurring >24h apart or (2) one unprovoked seizure and 
at least 60% probability of further seizures, or (3) a previous diagnosis of an epileptic syndrome 
(Fisher et al., 2014).  
Epilepsy can be defined as “symptomatic” when it manifests as a consequence of 
metabolic or structural brain defects. In some cases, such a disorder can originate from a focal 
region, meaning that the seizure starts from a point around the lesion and may spread and 
involve the whole brain. Conversely, in other situations, the seizure may be generalized and 
begin simultaneously in both brain hemispheres. Typical brain lesions that may provoke 
epilepsy include tumors, stroke or hippocampal sclerosis. They may cause one of the most 
frequent and often pharmacoresistant epilepsy type, namely mesial temporal lobe epilepsy 
(Lerche et al., 2013). 
A second group of epileptic disorders has a genetic origin. These epileptic disorders are 
called “idiopathic” (Epilepsy, 1989), but use of the term “genetic” has been recently proposed 
(Berg et al., 2010). They are a consequence of genetic defects, without any structural lesions 
and with a resulting phenotype that can vary from mild for the “idiopathic/genetic generalized 
epilepsies” (IGE/GGE) to severe, for the “epileptic encephalopathies” (EEs) (Lerche et al., 
2013). A majority of the mutations causing epilepsy affects voltage- or ligand-gated ion 
channels, but mutations in non-ion channels genes were identified as well as genetic cause of 
epilepsy. Interestingly, many of these genes mainly encode for proteins, which interact with 
ion channels or present a part of the synaptic complex (Weber & Lerche, 2008; Carvill et al., 
2014; Schubert et al., 2014). A variation of ion charges due to mutations affecting ion channels 
could produce an imbalance between glutamate-mediated excitation and GABA-mediated 
inhibition, thus leading to a condition of neuronal hyperexcitability and epileptic seizures. 
                                                                                                                                                              Introduction 
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2.1.1 Idiopathic epilepsies 
As mentioned before, idiopathic epilepsies are a consequence of genetic mutations. In 
the last twenty years a number genes from all major ion channel categories have been linked 
to different types of epilepsy. Especially the development of new DNA sequencing techniques, 
including whole exome and whole genome sequencing, contributed to the detection of rare 
and common variants affecting known or novel disease genes (Weber & Lerche, 2008; Myers 
& Mefford, 2015). It is believed that only a small percentage of the idiopathic epilepsies are 
due to single genes mutations and, therefore, monogenic, whereas most of them are caused 
by mutations in more than one gene and thus are polygenic (Dibbens et al., 2007). In 
particular, the monogenic forms include rare focal epilepsy disorders, whereas the more 
common idiopathic generalized epilepsies (IGEs) belong to the latter category. 
 The first ion channel mutation identified in an inherited form of epilepsy was found in 
the gene CHRNA4, encoding the alpha 4 subunit of the neuronal nicotinic acetylcholine 
receptor (Steinlein, 1995) and causing autosomal dominant nocturnal frontal lobe epilepsy 
(ADFNLE). Soon after, mutations in potassium channels KCNQ2 and KCNQ3 were identified as 
responsible for the benign familial neonatal seizures (BFNS) (Biervert et al., 1998). Beside 
BFNS, other forms of benign seizures include the benign familial neonatal-infantile seizures 
(BFNIS), caused by SCN2A mutations and benign familial infantile seizures (BFIS) linked to the 
presynaptic protein encoding gene PRRT2 (Herlenius et al., 2007; Schubert et al., 2012).  
The IGE forms include (i) absence epilepsies, characterized by a brief loss of 
consciousness, or (ii) generalized epilepsy including childhood absence epilepsy (CAE), juvenile 
absence epilepsy (JAE), juvenile myoclonic epilepsy (JME) and epilepsy with generalized tonic-
clonic seizures on awakening (EGTCA) (Crunelli & Leresche, 2002). Several mutations causing 
IGE were identified in -aminobutyric acid receptor A (GABAAR) and associated with childhood 
absence epilepsy (GABRG2, (Wallace et al., 2001)) or juvenile myoclonic epilepsy (GABRA1, 
(Cossette et al., 2002)). Mutations in sodium channels (Nav1.1, (Escayg et al., 2000)) are 
responsible for genetic epilepsy with febrile seizures plus, in which the seizures occur in 
conjunction with fever. Moreover, during the last decades the number of IGE-related variants 
has been continuously increasing (Steinlein, 1995; De Fusco et al., 2000; Jouvenceau et al., 
2001; Aridon et al., 2006). Interestingly, it is a deletion on Chromosome 16 that has the highest 
frequency in IGE patients (de Kovel et al., 2010).  
 
                                                                                                                                                              Introduction 
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2.1.2 Epileptic encephalopathies 
Epileptic encephalopathies (EEs) are severe types of epilepsies which occur early in life 
and are characterized by pharmacoresistant epilepsy, electroencephalographic abnormalities, 
and intellectual disability, due to progressive cerebral dysfunction. For this reason, this 
subgroup of epilepsies encompasses complex and heterogeneous genetically inherited 
disorders, difficult to diagnose and to treat. Estimated 40% of seizures occurring during first 
three years of life are due to epileptic encephalopathies (Nieh & Sherr, 2014). 
 Recently, exome sequencing and whole genome copy number variant (CNV) analysis 
has suggested that mutations causing EEs often represent sporadic cases, occurring “de novo”, 
or for the first time in a family. De novo mutations in the voltage-gated sodium channel Nav1.1 
(SCN1A gene) are the most common variants associated with a severe childhood epileptic 
encephalopathy, namely Dravet syndrome. Nevertheless, inherited autosomal dominant and 
recessive mutations or X-linked mutations were also identified (Allen et al., 2013; Duszyc et 
al., 2015).  
The most common early and mild childhood onset EE are Ohtahara Syndrome, Dravet 
syndrome, West Syndrome and Lennox-Gastaut Syndrome. The seizure onset may occur in 
the first months of age, but also in the first years of life (3 to 7 years) as for the Lennox-Gastaut 
Syndrome (Nieh & Sherr, 2014).  
2.2 GABAA Receptors structure and function 
Synaptic inhibition in the central nervous system (CNS) is a result of -aminobutyric 
acid (GABA) signaling. The fast inhibition mediated by GABA takes place through the ligand-
gated GABAA receptors (GABAARs) in the brain and GABACR in the retina. Once GABA binds to 
GABAAR, the channel opens, and the permeability to chloride and bicarbonate ions increases. 
This process leads to a hyperpolarized post-synaptic response in neurons, which decreases the 
probability of an action potential to occur. Besides binding to GABAAR or GABACR, the GABA 
transmitter can also mediate a slower and more sustained inhibition by binding to the 
metabotropic GABABR (Farrant & Nusser, 2005; Jacob et al., 2008). 
GABAARs are pentameric assemblies of different subunits that form the pore of the 
channel. 19 subunits have been identified so far:  (1-6), (1-3), (1-3),,, , ,  (1-3). 
Furthermore, the composition of the receptor can also vary due to alternative splicing of some 
                                                                                                                                                              Introduction 
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subunits. Each subunit shares a common structure and is formed by four transmembrane 
domains (TMs), a long N-terminal domain on the extracellular side, and a large intracellular 
loop between TM3 and TM4. The N-terminal domain mediates the ligand binding, and the 
TM3-TM4 loop is responsible for the interaction with scaffolding proteins like gephyrin 
(Alldred et al., 2005). The TM2 domains of the five subunits form the pore of the channel (Fig. 
1 A, B). The most common composition of the receptor in the mammalian brain is made by 
two  subunits, two  subunits and one  subunit, 122 representing ca. 60% of the whole 
GABAAR population in brain (Mohler, 2006).  
Receptors composed by 1, 2, 3, or 5 subunits, coupled with  and  subunits, are 
sensitive to benzodiazepines and are localized at the post-synaptic site. The only exceptions 
to this rule are 5-containing GABAA receptors, localized extrasynaptically, where they 
mediate tonic inhibition, a more sustained form of inhibition mediated by ambient 
concentrations of GABA. Other receptors with extrasynaptic localization are those containing 
4 or 6 subunits. Furthermore, these receptors are insensitive to benzodiazepines. Thorough 
analysis of the GABAAR expression in the mouse brain revealed high levels of 1, 2, 3, 4, 
1, 2, 3 subunits and moderate presence of 5, 1 and 2 in the cortex. In hippocampus, 
the most abundant are 1, 2, 4, 5, 1, 2, 3, 2. The thalamus shows higher 
expressionf1, 4, 1, 2, and a milder expression of 2, 3, 3, 1 and 2. 6 is found 
Figure 1. GABAAR structure. (A) Each GABAAR subunit consists of four 
transmembrane domains (TMs), a big extracellular N-terminal and a big 
intracellular loop between TM3 and TM4. (B) pentameric assembly of GABAAR 
showing the binding sites of GABA (between  and  subunits) and of 
benzodiazepines  (between  and  subunits).  
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only in the cerebellum. Interestingly, the 3 subunit is the only  subunit expressed in the 
nucleus reticularis of the thalamus (NRT, Hortnagl et al., 2013). 
2.2.1 Dysregulation of GABAARs in epilepsy 
Mutations causing epilepsy have been identified in different subunits of the GABAAR, 
including 1 (Cossette et al., 2002; Maljevic et al., 2006), 2, 3 (Allen et al., 2013), 2 (Harkin 
et al., 2002; Ishii et al., 2014) and  subunits (Dibbens et al., 2004). These mutations were 
identified in patients with different epilepsy syndromes, ranging from the less severe IGE to 
the more severe EE. Mutations in 1 and 2 subunits were found in families with Dravet 
Syndrome (Ishii et al., 2014; Carvill et al., 2015) and Infantile Spasms (Allen et al., 2013), and 
3 mutations were associated with Lennox-Gastaut syndrome (Allen et al., 2013). Functional 
assays revealed that these mutations cause a loss of channel function. The mechanisms 
leading to reduced GABA-induced currents include a lower surface expression, reduced 
protein stability, reduced GABA-sensitivity and altered gating kinetics (Kananura et al., 2002; 
Krampfl et al., 2005; Maljevic et al., 2006; Hirose, 2014). Decreased GABA-induced currents 
will have a dramatic repercussion on the physiological balance between inhibition/excitation 
in the brain, and may be the reason for increased seizure activity in patients (Benarroch, 2007). 
Proconvulsive activity of GABAAR antagonists, such as bicuculline or picrotoxin, shown in 
different in vitro and in vivo assays supports this hypothesis (Cortez et al., 2010; Hedrich et al., 
2014).  
Trafficking mechanisms have been suggested as one of the reasons for the disruption 
of normal GABAergic activity. GABAARs undergo complex trafficking processes, and mutations 
in the GABA subunits might contribute to the loss of the expression of these receptors at the 
synapses. Moreover, scaffold proteins, such as gephyrin, bind intracellularly to the GABAAR 
receptors, clustering them at the synapses and loss of interaction with these proteins 
disorganize the complex synaptic localization of the GABAARs (Studer et al., 2006). The 
processes described above decrease the number of GABAARs expressed at the synapses, thus 
leading to reduced synaptic inhibition, lower seizure threshold and a decreased sensitivity to 
anti-epileptic drugs binding to GABAARs. 
Mouse studies are important for the understanding of the complex genetic 
heterogeneity of epileptic disorders seen in patients. In the last twenty years, several 
knockout (KO) mouse models of different GABAAR subunits were developed (DeLorey et al., 
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1998; Mihalek et al., 2001; Kralic et al., 2002; Rudolph & Mohler, 2004), but so far only one 
knock-in mouse model of epilepsy, carrying the R43Q mutation in the 2 subunit, was 
produced and analyzed. This mouse model displays spike-wave discharges and absence-like 
seizures similar to those detected in patients (Reid et al., 2013). 
2.3 GABAB receptors 
 GABAB receptors are seven transmembrane domain guanine nucleotide-binding (G) 
protein-coupled receptors. After binding of their endogenous agonist GABA, they mediate 
slow and sustained inhibitory responses through the modulation of K+ and Ca2+ channels. 
Perturbation of GABABR responses during development may alter the inhibitory/excitatory 
processes in the brain, resulting in several neurological disorders, including absence seizures. 
Figure 2. GABABR structure. The GABABR is formed by two subunits, GABAB1 and GABAB2. Each subunit 
is formed by seven transmembrane domains, a big extracellular N-terminus and an intracellular C- 
terminus. The N-terminal domain of the GABAB1 subunit is responsible for binding the ligand, while the 
C-terminal one of GABAB2 interacts with the G-protein to activate the K+ channels Kir3 at postsynaptic 
sites or to inhibit the Ca2+ channels presynaptically.  
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Rodents treated with baclofen, the GABABR agonist, show an absence seizure phenotype, 
which in contrast can be suppressed by the treatment with the GABABR antagonist CPG35348 
(Cortez & Snead, 2006; Wu et al., 2007).    
The cloning of GABABR has identified two GABAB genes, GABAB1 and GABAB2. Each gene 
encodes for a different subunit comprising a long N-terminal domain, a heptahelical 
transmembrane domain and a C-terminal intracellular tail (Lujan & Ciruela, 2012). To be 
functional, GABABRs require heterodimerization of the two subunits (Pin, 2007). The N-
terminus of the GABAB1 binds ligands, whereas the C-terminal domain of the GABAB2 subunit 
facilitates the G-protein activation. The C-terminal domains of both subunits interact with 
each other and are the target of several associated proteins, including transcription factors, 
scaffolding and adaptor proteins (Pin et al., 2004).  
GABABR signaling occurs through activation of Gi/o proteins. Their primary action is the 
inhibition of presynaptic voltage-gated Ca2+ channels (N type, Cav2.2, or P/Q type, Cav2.1), 
which results in inhibition of neurotransmitter release. They also activate postsynaptic K+ 
currents (the G-protein-coupled inward rectifying potassium channels, GIRK or Kir3) that 
results in hyperpolarization and late inhibitory postsynaptic potentials (Fig. 2). In addition, 
through Gi/o  subunit, they inhibit the adenylyl cyclase, and therefore the cyclic adenosine 
monophosphate (cAMP)-protein kinase A pathway, which stands as necessary for the 
phosphorylation and upregulation of NMDA receptors (Ulrich & Bettler, 2007).  
GABABRs have a broad distribution in the brain. High expression of these receptors was 
found in the olfactory bulb, neocortex, hippocampus, thalamus and cerebellum (Fritschy et 
al., 1999). Moreover, mice lacking GABABR have spontaneous epileptiform activity (Schuler et 
al., 2001).  
No epilepsy-causing mutations have been identified in the GABABRs genes until 
recently, when two de novo mutations in the GABAB2 subunit were found in patients with 
severe epilepsy. Both mutations are located on the sixth transmembrane domain. The first 
mutation was found at the amino acid position 695 wherein a serine was exchanged by an 
isoleucine (S695I) and the second mutation at the amino acid position 705 wherein an 
isoleucine was exchanged by an asparagine (I705N). The functional consequences of these 
mutations are investigated in the current thesis (Appenzeller et al., 2014).   
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2.4 ClC-2 channels 
The first ClC channel was cloned from Torpedo marmorada 25 years ago by Jentsch et 
al. (1990). This channel was called ClC-0 and used to define the ClC family. ClCs are anion 
channels and transporters that include nine human members. Four of them are ClC channels, 
ClC-1, ClC-2, ClC-Ka and ClC-Kb, while the other five are anion-proton transporters, ClC-3 
through ClC-7 (Scheel et al., 2005). The ClC channels and transporters have different 
physiological roles. The ClC transporters are mainly expressed intracellularly, in cellular 
compartments such as lysosomes and endosomes, where they contribute to the regulation of 
these organelles. In contrast, the ClC channels are mainly expressed on the surface 
membranes of excitable and epithelial cells, where they regulate either membrane excitability 
or they participate to the transport of water and electrolytes (Stölting et al., 2014). Analysis 
of the crystal structure in prokaryotic cells has revealed that ClC channels and transporters 
share a similar structure (Dutzler et al., 2002). The ClC proteins were identified as dimers, and 
each monomer is composed of 18 transmembrane helices. Intracellularly, each monomer 
ends with a long C-terminal domain containing two conserved cystathionine--synthase (CBS) 
Figure 3. ClC structure. Each channel is a dimer and each monomer is formed by 18 
transmembrane domain helices. The C-terminus contains two CBS domains responsible for 
the gating properties of the channels.  
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domains (Fig. 3). The CBS domains are important for channel gating, and their removal can 
cause loss of channel function (Garcia‐Olivares et al., 2008).  
ClC-2 channel was cloned shortly after ClC-1 (Thiemann et al., 1992). This channel is 
broadly expressed in excitable and not excitable cells. In the brain, it is highly expressed in 
pyramidal cells of the hippocampus, in Purkinje cells of the cerebellum, but also in the cortex, 
thalamus and other regions of the brain (Smith et al., 1995; Sık et al., 2000). Besides neurons, 
a high expression was observed in glial cells. Outside the CNS it is found in epithelia and the 
hearth (Thiemann et al., 1992). ClC-2 channel activates slowly upon hyperpolarization, but it 
may also be activated by cell swelling and mild acidic extracellular pH, and it shows inward 
rectification (Staley, 1994). The opening probability of the channel depends on the 
concentration of intracellular chloride. More precisely, the channels open at membrane 
potentials more negative than the chloride equilibrium potential of the cell. Under these 
circumstances, ClC-2 channels allow chloride ions to exit the cell until the chloride equilibrium 
potential equals with the membrane potential, contributing to the stabilization of intracellular 
anion concentration in the cells in which the channel is expressed (Stölting et al., 2014).   
ClC-2 also has a role in glial cells, where it associates with an accessory subunit and cell 
adhesion molecule, GlialCAM. In heterologous systems, it was shown that this association is 
responsible for keeping the channel in a constant open state (Jeworutzki et al., 2012). 
However, recordings from brain slices derived from GlialCAM KO mice showed that ClC-2 
currents were not significantly different from the wildtype (WT), indicating that the effect is 
less pronounced in vivo than in heterologous systems (Hoegg-Beiler et al., 2014).  
ClC-2 variants were reported in patients with idiopathic generalized epilepsy 
(D’Agostino et al., 2004; Saint-Martin et al., 2009), but additional mutations, which disrupt 
channel function, have been reported  in patients with leukoencephalopathy and brain matter 
oedema (Depienne et al., 2013). These patients did not present any epileptic phenotype, 
suggesting that ClC-2 alone cannot be a major cause of epilepsy. Similar with the patients` 
phenotype, the ClC-2 KO mice show vacuolization of the white matter. Additionally, these 
mice have retinal and testicular degeneration (Bösl et al., 2001; Blanz et al., 2007). Eventhough 
they show abnormal cortical activity with an increased susceptibility to induced seizures 
(Cortez et al., 2010), no spontaneous seizures have been detected (Bösl et al., 2001; Blanz et 
al., 2007).  
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The physiological role of these channels is not fully understood. It is believed that ClC-
2 acts as an exit valve for chloride, therefore reducing the intracellular chloride concentration, 
which is normally increased by GABAAR (Rinke et al., 2010). Thus, ClC-2 would help to keep 
the hyperpolarizing effect of GABAAR (Staley et al., 1996). This is a similar role to the 
potassium-chloride cotransporter 2 (KCC2), which is the major chloride extruder in neurons 
(Kaila et al., 2014). Oppositely, a modeling study suggested that in physiological conditions 
ClC-2 channels are open at positive potentials, leading Cl- into the cells and therefore directly 
contributing to the increased intracellular Cl- and neuronal excitability (Ratté & Prescott, 
2011).   
2.4.1 The thalamo-cortical system 
 The thalamus is a subcortical region responsible for the generation of synchronized 
oscillatory activity in the cortex, in normal and pathological conditions (Steriade et al., 1993).  
In physiological conditions, thalamocortical oscillations are responsible for generating the 
sleep spindles during non-rapid eyes movement (REM) sleep. In pathological conditions, the 
thalamocortical system can generate spike and wave discharges occurring at 2.5-4 Hz in 
patients with idiopathic generalized epilepsy and more specifically with absence seizures 
(D'Arcangelo et al., 2002).      
Figure 4.  Thalamocortical system. The 
relay neurons receive inhibitory 
connections from the nucleus reticularis 
thalami (NRT) and excitatory 
connections from pyramidal cells of the 
cortex. In turn they send their excitatory 
connections to the NRT and back to the 
cortex. The cortex activates relay 
neurons in the ventrobasal complex 
(VB) and the inhibitory neurons in the 
NRT, which inhibit each other through 
electric synapses and inhibit the relay 
neurons, activating low threshold Ca2+ 
channels in these neurons, which give 
rise to bursting activity. Adapted from 
Hedrich et al. (2014). 
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Three neuronal populations are involved in this circuit: (i) the thalamic relay neurons 
in the ventrobasal complex (VB), (ii) the inhibitory neurons of the nucleus reticulari thalami 
(NRT), formed by a thin layer of GABAergic neurons surrounding the thalamus, and (iii) the 
pyramidal neurons in the fifth cortical layer (Fig. 4). The thalamic relay neurons can activate 
the cortical pyramidal neurons in two ways: in a tonic mode, which in normal conditions occurs 
during REM sleep, or in a burst mode, which occurs during non-REM sleep. The burst mode is 
mediated by T-type Ca2+ channels that are activated by hyperpolarization and mediate low-
threshold depolarization with bursts of action potentials (Lee et al., 2014). The rhythmic 
oscillatory activity is generated by the inhibitory neurons of the NRT. These neurons send their 
inputs to the relay neurons of the VB, hyperpolarizing them and activating the T-type Ca2+ 
channels and the burst activity. The relay neurons, in turn, send their projection to the 
inhibitory neurons in the NRT and to cortical pyramidal neurons starting another cycle of the 
oscillation. The pyramidal cells of the cortex, in turn, activate the inhibitory neurons in the 
NRT and the relay neurons in the VB (Chang & Lowenstein, 2003). A characteristic feature of 
inhibitory neurons of the NRT is that they are reciprocally connected through electrical 
synapses and can inhibit each other (Landisman et al., 2002). In pathological conditions, such 
as absence epilepsy, the intra-NRT synaptic inhibition is reduced, transforming  the normal 
synchronous activity into a hypersynchronous state, which leads to seizure-like activity 
(Huntsman et al., 1999).  
Interestingly, the KCC2 transporter has an extremely low expression in the inhibitory 
neurons of the NRT, which makes the GABAergic synapses in these cells to act through 
depolarization (Sun et al., 2012). Furthermore, the absence of KCC2 in the inhibitory neurons 
of the NRT makes it easier to isolate the ClC-2 contribution to the thalamocortical circuit, 
which is one of the focuses of this study.  
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2.5 Aims 
Within this thesis, three projects were developed with an overall aim to better 
understand the role of the GABAergic system in the generation of seizures and epilepsy. For 
this purpose, newly detected mutations affecting one GABAA and one GABAB encoding gene 
have been studied using a heterologous expression system. Moreover, the potential 
physiological role of the ClC-2 channel, related to the function of the GABAergic system has 
been investigated using a ClC-2 KO mouse model. 
Specific aims were as follows:  
1) To assess the functional defects of four novel mutations in the GABRA3 gene, 
encoding the 3 subunit of the GABAAR. The GABRA3 mutations have been 
detected by our collaborators for the first time in patients affected with different 
forms of epilepsy, from mild idiopathic generalized epilepsy to severe epileptic 
encephalopathy with intellectual disability and dysmorphic features. Functional 
consequences of these mutations were analyzed using the two-microelectrode 
voltage-clamp technique in Xenopus laevis oocytes as a heterologous expression 
system. 
2) To functionally analyze the first two epilepsy-causing mutations associated with 
the metabotropic GABAB receptors. These de novo mutations, found in the 
GABAB2R subunit encoded by the GABBR2 gene, were identified in patients affected 
by severe epileptic encephalopathies. The mutations were characterized by the 
two-microelectrode voltage-clamp technique and Xenopus laevis oocytes as a 
heterologous expression system. 
3) To analyze the role of ClC-2 channels in neurons, more specifically its contribution 
to the neuronal excitability. For this purpose, a ClC-2 channel KO mouse model was 
used and patch-clamp and extracellular recordings experiments were performed in 
thalamocortical brain slices of ClC-2 KO, heterozygous (HET) and WT littermates. 
Additionally, network activities of primary hippocampal neuronal networks were 
compared for the three phenotypes using microelectrode array (MEA) analysis.  
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3 Materials and Methods 
3.1 Molecular biology 
3.1.1 Vector constructs 
For oocytes measurements, the human cDNA of GABRA3 was inserted in the pcDNA 
3.1- vector. The WT construct was provided by Prof. Steven Petrou (Florey Institute of 
Neuroscience and Mental Health, Melbourne, Australia). cDNA encoding the human isoform 
of GABBR2 and the two constructs containing missense mutations (I705N and S695I) were 
synthesized and cloned into the pcDNA 3.1+ vector by Gene-Script. GIRK1 and GIRK2 clones 
were synthesized and cloned into pCMV-XL5 and pCMV-XL4 respectively, by Origene. The 
expression of all clones is guided by a Cytomegalovirus (CMV) promoter in mammalian cells. 
The T7 promoter sequence existed as a template for T7 RNA polymerase, which is catalyzing 
DNA-dependent RNA synthesis.  
3.1.2 Mutagenesis 
In this study, our collaborators (Dorit Lev, Tally Lerman-Sagie (Metabolic-Neurogenetic 
Clinic, Wolfson Medical Center, Holon, Israel), Esther Leshinsky-Silver (Institute of Medical 
Genetics, Wolfson Medical Center, Holon, Israel), Vera M. Kalscheuer (Department of Human 
Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany), Agnieszka 
Charzewska (Institute of Mother and Child, Department of Medical Genetics, Warsaw, 
Poland),  Nicola Specchio (Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, 
Italy), Giuseppe Capovilla (Department of Child Neuropsychiatry, Epilepsy Center, C. Poma 
Hospital, Mantova, Italy), Pasquale Striano (Pediatric Neurology and Muscular Diseases Unit, 
Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child 
Health, Institute “G. Gaslini”, Genova, Italy), Federico Zara (Laboratory of Neurogenetics and 
Neuroscience, Institute “G. Gaslini”, Genova, Italy)), identified four novel mutations in the 
GABRA3 gene (p.Q242L, p.T336M, p.T166M, p.G47R). Two de novo mutations in the GABBR2 
gene (p.I705N and p.S695I) were identified by the EuroEPINOMICS Consortium (Appenzeller 
et al., 2014). The GABBR2 variants were delivered by Gene-Script (see 3.1.1). Properties of 
each plasmid construct (regarding the inserted DNA, length and position of the insertion) are 
shown in Table 1. Site-directed mutagenesis was performed for the GABRA3 variants into the   
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Table 1.  Properties of the inserted mutations 
 
 
  Table 2. Primers sequences 
human cDNA using the QuickChange kit (Stragene, Agilent Technologies), GABRA3 WT as a 
template and mutagenesis primers shown in Table 2.  
The PCR conditions were as follows: 50 ng DNA template, 10x reaction buffer, 0.5 µl 10 
pmol/µl of each primer, 0.5 µl dNTPs, 0.5 µl PfuUltra Turbo polymerase, up to 25µl with 
Ampuwa water. Products were confirmed by agarose gel electrophoresis (1% agarose 
Gene Vector Mutation  Size of the insert  
     
hGABRA3 pcDNA 3.1- c.A725T/ p.Q242L 1478 bp      
 pcDNA 3.1- c.C497T/ p.T166M 1478 bp      
 pcDNA 3.1- c.C1007T/ p.T336M 1478 bp      
 pcDNA 3.1- c.G139A/ p.G47R 1478 bp      
hGABBR2 pcDNA 3.1+ c.T2114A/ p.I705N 2825 bp  
 pcDNA 3.1+ c.G2084T/ p.S695I 2825 bp  
Primer name Sequence Used for  
    
GABRA3 Q242L F 5´- GTTCTCGCTTGAACCTGTATGACCTTTTGGG - 3´ Mutagenesis  
GABRA3 Q242L R 5´ - CCCAAAAGGTCATACAGGTTCAAGCGAGAAC - 3´ Mutagenesis  
GABRA3 T166M-F 5´- CATAACATGACCATGCCCAACAAGCTG-3´ Mutagenesis  
GABRA3 T166M-R 5´- CAGCTTGTTGGGCATGGTCATGTTATG-3´ Mutagenesis  
GABRA3 T336M F 5´- GTGGCATATGCGATGGCCATGGACTGG - 3´ Mutagenesis  
GABRA3 T336M R 5´- CCAGTCCATGGCATCGCATATGCCAC - 3´ Mutagenesis  
GABRA3 G47R-F 5´- GGACATTGGCAGGCTGTCTCC- 3´ Mutagenesis  
GABRA3 G47R-R 5´- GGAGACAGCCTGCCAATGTCC- 3´ Mutagenesis  
GABRA3 seq-R 5´- CACAGTCGAGGCTGATCAGCG- 3´ Sequencing  
T7 - F 5´- TAATACGACTCACTATAGGG- 3´ Sequencing  
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dissolved in Tris/Borate/EDTA; the solution was supplemented with 20,000x Red safe dye). 
Gel image was obtained by fluorescence illumination. The correct PCR product was first 
treated with the restriction enzyme DPN1 for an hour at 37°C to allow the digestion of the 
template. 
3.1.3 Transformation 
5 µl of the PCR product were transformed in 50 µl Top 10 E. coli strain. After 30 minutes 
of incubation on ice, cells were heat shocked for 30 s at 42°C. 250 μl of pre-warmed SOC 
medium was added for recovery and cells were incubated at 37°C, shaking at 300 rpm for 60 
min. After recovery, cells were spread onto Ampicillin containing Agar plates (100 μg/ml 
Ampicillin; 10x Agar plates: 20 ml LB medium including 1.5% Agar).  
3.1.4 DNA purification 
Following overnight incubation at 37°C, resistant colonies that emerged on the LB 
plates were picked and inoculated in LB medium (10 g/l B-trypton, 5 g/l Bactoyeast, 10 g/l 
NaCl with pH 7.0 and autoclaved) containing Ampicillin (100 μg/ml) and cultured overnight at 
37°C. On the next day, mini-prep was performed to obtain plasmid-DNA from the bacterial 
cultures by using Illustra plasmid Prep Mini Spin kit (GE Healthcare). For larger plasmid DNA 
amounts maxi-prep was performed using Genopure plasmid Maxi prep kit (Roche). 
Concentration of the plasmid DNA was measured using the Nanodrop spectrophotometer. 
3.1.5 Sequencing 
 The correct insertion of the mutations was confirmed and additional mutations 
excluded by Sanger sequencing, performed by GATC Biotech Company. The used primers are 
shown in Table 2. Reference sequences for GABRA3, obtained from the National Center for 
Biotechnology Information (NCBI) nucleotide database, has Accession number: NM_000808. 
Sequences obtained from GATC were analyzed by CLC Sequence Viewer software (CLC Bio, 
QIAGEN).  
3.1.6 DNA linearization 
After obtaining the plasmid DNA in large quantities, the next step was to linearize the 
circular plasmid DNA to ensure the production of defined length RNA transcripts during the in 
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vitro RNA synthesis. For linearization, 10 μg of plasmid DNA, 2 μl restriction enzyme (that cuts 
downstream of the insert), 5 μl of respective enzyme buffer (10x) and up to 50 μl distilled 
water were mixed and incubated at 37°C for 2 h. For GABRA3, linearization was performed 
with HindIII, whereas for GABRB2 and GABRG2 with BamHI. Linearization for GABBR1 and 
GABBR2 was performed with XhoI and XbaI respectively, whereas GIRK1 and GIRK2 were 
linearized using SacII and SmaI respectively. DNA restriction was followed by a 
phenol/chloroform extraction to remove proteins from the nucleic acid samples. 100 μl DEPC-
treated water and 150 μl phenol/chloroform were added to the DNA mixture, followed by a 
centrifugation step at 13,000 g for 2 min. The resulting upper phase (which includes the nucleic 
acids) was collected and 100 μl chloroform/isoamylalcohol added to the solution. After gently 
mixing and centrifuging (13,000 g, 2 min), the DNA was precipitated with 10 μl Ammonium-
acetate and 300 μl 100% Ethanol, mixed gently and incubated at -80°C for 30-60 minutes. After 
this incubation, the mixture was centrifuged (12,000 g, 15 min, at 4°C), the supernatant 
discarded and the pellet was washed with 200 μl of 70% Ethanol and centrifuged (12,000 g, 
15 min, 4°C). As the last step, the pellet was air-dried, dissolved in 10 μl DEPC-treated water 
and the linearized DNA was confirmed by Agarose gel electrophoresis.  
3.1.7 RNA preparation 
The linearized DNA-constructs were transcribed into capped RNAs using in vitro RNA 
synthesis. As the constructs in this study comprise T7 promoter, T7 polymerase was used to 
transcribe the corresponding RNA. Mixtures including 1 μg linearized DNA, 2.5 μl of T7 
polymerase buffer (10x), 1 μl rNTPs, 2.5 μl cap analogue, 1 μl RNAse inhibitor, 2 µl T7 
polymerase and up to 25 µl with DEPC-treated water were incubated at 37°C for 60 min. To 
degrade the DNA template, the products were further incubated with 1 µl of 10U DNase at 
40°C for 15 min. Transcript mixture together with 100 μl DEPC-treated water and 125 μl 
Phenol/Chloroform was added in a phase-lock gel tube to perform phenol-chloroform 
extraction. After a centrifugation step (14,000 rpm, 5 min), 375 μl 100% Ethanol and 12.5 μl 
3M Na+ Acetate (pH 5.2) were added to the supernatant, mixed, and incubated for 30 min at 
-80°C. Incubation was followed by a further centrifugation step (14,000 rpm 15 min, at 4°C) 
and the pellet was washed with 500 μl 70% Ethanol. After a final centrifugation (14,000 rpm, 
15 min at 4°C), the pellet was air dried and dissolved in DEPC-treated water. The RNA 
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transcripts were confirmed via Agarose gel electrophoresis and the concentrations were 
measured using the Nanodrop spectrophotometer.   
3.1.8 Genotyping  
ClC-2 mice used for MEA experiments or acute brain slices experiments were 
genotyped after each experiment. Tails or ear biopsies were digested over night at 55°C with 
proteinase K in lysis buffer (in mM: 50 Tris-HCl pH 7.5, 50 EDTA pH 8, 100 NaCl, 5 DTT, 0.5 
Spermidine, 2 % SDS (v/v)). After the digestion, the DNA was precipitated in 100% of 
isopropanol, washed in 70% of ethanol and dissolved in Ampuwa water. PCR reaction was 
performed using primers listed in Table 3, and the obtained product visualized on the agarose 
gel. The expected size of the bands was 200 bp for the WT and 300 bp for the KO allele. 
Table 3 Primers used for genotyping 
 
3.2 Xenopus laevis oocyte experiments 
3.2.1 Oocyte preparation and RNA injection 
Xenopus laevis oocytes are widely used as a heterologous expression system. The large 
size of the mature oocyte (≈ 1.2 mm diameter) allows easy in vitro manipulation and injection 
of mRNAs or DNAs. Moreover, the oocytes express low levels of endogenous channels, making 
it easier to distinguish the heterologous ones. For ion channel expression, full mature oocytes 
in stage V-VI were used.    
The use of animals and all experimental procedures were approved by local authorities 
(Regierungspraesidium Tuebingen, Tuebingen, Germany). Oocytes were obtained from the 
Institute of Physiology I, Tübingen, or purchased from EcoCyte Bioscience (Castrop-Rauxel, 
Germany). Preparation of oocytes for two-electrode voltage clamp (TEVC) recordings included 
treatment with collagenase (1mg/ml of type CLS II collagenase, Biochrom KG, Berlin, Germany) 
in OR-2 solution (mM: 82.5 NaCl, 2.5 KCl, 1 MgCl2 and 5 Hepes, pH 7.6), to remove the external 
Primer name Sequence 
ClC-2 KO - F 5´- ATGTATGGCCGGTACACTCAGGAACTC - 3´ 
ClC-2 NeoKO - F 5´- CCT GGA AGG TGCCACTCCCACTGTCC - 3´ 
ClC-2 KO - R 5´- ACACCCAGGTCCCTGCCCCAATCTGG - 3´ 
                                                                                                                                         Materials and Methods  
27 
 
layer containing the follicular cells, surrounding the oocytes. This process was necessary 
because the follicular layer expresses ion channels which could interfere with further 
electrophysiologically measurements and could additionally impair the RNA injection. Next, 
the oocytes were washed and stored at 16 °C in Barth solution (mM: 88 NaCl, 2.4 NaHCO3, 1 
KCl, 0.41 CaCl2, 0.82 MgSO4 and 5 Tris/HCl, pH 7.4 with NaOH) supplemented with 50 µg/ml 
gentamicin (Biochrom KG, Germany). To compare current amplitudes of WT and mutant 
channels, the same concentrations of cRNA were injected on the same day using the same 
batch of oocytes plated in 96 well-plates and measured 3 days after injection. To produce a 
functional GABAA receptor, the combination of subunits injected was 322s in a 1:1:2 ratio. 
All cRNA concentrations were adjusted to 2 µg/µl and 70 nl of the corresponding cRNA were 
injected using Robooinject® (Multi Channel Systems, Reutlingen, Germany, Fig.5). For GABAB 
receptor expression, 50 or 70 nl of GIRK1, GIRK2, GABBR1, GABBR2 (WT or mutation) were 
injected in a 1:1:2:2 ratio with a final RNA concentration of 1.5 µg/µl.  
Figure 5. Automated Roboinject used for RNA injection into Xenopus laevis oocytes. (A) 
In the middle, the plate carrier can be observed, containing a 96 well plate, in which each 
well can potentially contain one oocyte. Additionally, the plate carrier contains spaces for 
eight different RNA tubes that could be used for injection. The injection needle is shown 
above the plate. (B) Stage V Xenopus laevis oocytes (≈ 1.2 mm diameter); the brown 
pigmented half, the so-called animal pole, is containing the nucleus, while the light half 
is the vegetal pole, which contains the primary energy source of the oocyte. The RNA was 
injected in the animal pole.   
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3.2.2 Automated oocyte two-electrode voltage clamp 
GABA-evoked currents in oocytes were recorded at room temperature (20-22°C) using 
the fully automated Roboocyte2® (Multi Channel Systems, Reutlingen, Germany). Because of 
the large size of the oocytes, the two-electrode voltage clamp (TEVC) technique was applied 
(Fig. 6). TEVC is based on the use of two low resistance electrodes: one is measuring the 
voltage, and the other one is injecting the current. Prepulled and prepositioned intracellular 
glass microelectrodes had a resistance of 0.3–1 MΩ when filled with 1 M KCl/ 1.5 M KAc. The 
bath solution was ND96 (in mM: 93.5 NaCl, 2 KCl, 1.8 CaCl2, 2 MgCl2, 5 Hepes, pH 7.5). Currents 
were sampled at 1 kHz. The holding membrane potential was set at -70 mV. Different GABA 
concentrations (in µM: 1, 3, 10, 40, 100, 300, 1000) diluted in ND96 solution, were applied for 
15 s to activate the GABAA channels. GABAB expressing oocytes were incubated with KD40 
solution (in mM: 40 KCl, 52 NaCl, 5 Hepes, 1.8 CaCl2, 1 MgCl2, pH= 7.4) for 20 min to one hour 
before the recording. To activate GABAB channels, GABA was diluted in KD40 and different 
concentrations (in µM: 0.001, 0.1, 1, 3, 10, 100) were applied for 60s. 
Figure 6. The fully automated Roboocyte 2. Left: plate carrier with the 96 well plate containing the 
oocytes and measuring head above the plate. Right: Perfusion system with 12 valves available for the 
agonist application. 
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3.3 Cell culture 
3.3.1 Mouse hippocampi cell culture preparation 
The hippocampi were collected from E17.5 pregnant Clcn2 wildtype (WT), 
heterozygous (HET) and knockout (KO) mouse (BL.6-CLCN2<<tm1Mlv>>/Hlerc; Prof. James E. 
Melvin, University of Rochester). After suppressing the pregnant mice with CO2, the embryos 
were removed from the uterus and decapitated. For genotyping, a piece of tail was collected 
for each embryo. The brain was removed, washed in HBSS and the hippocampi were isolated.  
 
Table 4. Cell culture media, drugs and other materials 
The dissociation of the hippocampi was performed under a sterile hood. After washing the 
hippocampi in HBBS, they were incubated in 0.05% of Trypsin at 37°C for 15 min. The reaction 
was stopped with DMEM supplemented with 10% FCS and penicillin/streptomycin. 
Media for  primary  
hippocampal cell culture 
Ingredients Company  
DMEM + 44.75 ml DMEM  Gibco   
 5 ml FCS  PAN-Biotech, Aidenbach   
 250 µl p/s (10 mg/ml)  Biochrom, Berlin  
Neurobasal + 58.65 ml Neurobasal  Gibco   
 1 ml B27  Gibco   
 250 µl L-glutamine (200 mM)  Gibco   
 p/s (10 mg/ml) 100 µl Biochrom, Berlin   
Other materials and  
drugs used for cell culture 
   
 PBS Gibco  
 HBSS PAA Laboratories, Cölbe  
 Poli-D-lysin (PDL) 0.1 mg/ml Sigma-Aldrich  
 1:200 in HBSS Laminin (1mg/ml)  Sigma-Aldrich  
 0.05 % Trypsin  Gibco  
 Bicuculline    Sigma-Aldrich  
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Subsequently, the hippocampi were mechanically dissociated and the cell suspension filtered 
through a 40 µM cell strainer. 120.000 cells/100 µl DMEM, supplemented with 10% FCS and 
penicillin/streptomycin, were plated on each MEA dish. The MEA dishes were coated with 
poly-D-lysine (0.1 mg/ml) overnight at 4°C, followed by washing with water (2x) and PBS (1x). 
After washing, the dishes were dried and sterilized with the UV light (20 min) in the cell culture 
hood. Subsequently, 10-15 µl of laminin were placed in the middle of the dish and kept 
overnight at 4°C. Laminin was removed shortly before plating of cells. Four hours after plating, 
Neurobasal media supplemented with B27, penicillin/streptomycin and L-glutamine was 
added to each MEA (Table 4). Half of the media was exchanged every 3-4 days. 
3.3.2 Network activity recordings using the microelectrode arrays (MEAs) 
MEA dishes were bought from Multi Channel Systems (Reutlingen, Germany). A 
standard MEA dish has a square recording area of 700 µm to 5 mm of length. In this area, 60 
planar titanium nitride (TiN) electrodes of 30 µm size are aligned in an 8x8 grid (Fig. 7). 
To record spontaneous activity of primary Clcn2 WT and KO, primary hippocampal 
neurons MEA dishes were prepared as described above (see section 3.3.1). The recordings 
were performed after 11, 18 and 25 days in vitro (DIV). According to the specification of the 
manufacturer, electrodes had an input impedance of 30-50 kΩ. Signals from all 60 electrodes 
were simultaneously sampled at 25 kHz, visualized and stored using the software MC_Rack 
provided by Multi Channel Systems. Extracellular recordings were performed at 37°C as 
follows: after two minutes of habituation, two minutes of recordings were done in the control 
condition (only media). Bicuculline (final concentration 10 µM) was added to the MEA dish 
and after two minutes of incubation time, two additional minutes were recorded. After the 
Figure 7. MEA chip. (A) Classical MEA chip with 60 extracellular electrodes. (B) The electrode spacing 
was 200 µm and the diameter of each electrode 30 µm. (C), (D), Magnification of one TiN microelectrode.   
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recording, each MEA dish was washed with the NB medium to remove any remains of the 
drug.  
3.4 Acute thalamo-cortical brain slice preparation 
For patch-clamp and extracellular experiments, acute brain slices preparation from 
Clcn2 WT, HET or KO mice were prepared according to Agmon and Connors, 1991. Mice were 
analyzed between post-natal day (P) 10 and 18. To prepare the brain slices, the animals were 
anesthetized with Isoflurane (Cp-Pharma, Burgdorf, Germany) and quickly decapitated. The 
head was placed in the ice-cold cutting artificial cerebrospinal fluid (aCSF, Table 4), saturated 
with carbogen (95 % O2, 5 % CO2). Subsequently, the brain was carefully removed and placed 
on a glass ramp with a 10° slope. Using a sharp single edge blade, the brain was vertically cut 
at a 55° angle, about one-third from the anterior part (Fig. 8). Therefore, the special cut of the 
brain, using a 10° slope and a 55° angle, was made to allow the intact connectivity between 
Figure 8. Preparation of acute thalamocortical brain slices. (A) The brain was laid on the 
10° angle ramp. (B) The 55° angle used to cut vertically through the tissue. (C) The glued 
brain on the vibratome stage and the position of the slices containing the full connectivity 
between thalamus and cortex. Figure modified from Agmon and Connors (1991). 
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the cortex and the thalamic area, including the nucleus reticularis thalami (NRT) and the 
ventrobasal (VB) nucleus of the thalamus. The anterior part of the cut tissue was discarded 
while the posterior part was glued onto a Vibratome stage. The cut surface was glued down 
to the stage, with the dorsal part of the brain facing the blade. A small agar piece glued on the 
stage was used to hold the brain in this conformation. The tissue was completely immersed in 
cutting aCSF and three to four coronal 500 µM slices were cut and discarded. Once the 
thalamic area was reached, three to four 400 - 450 µM thalamocortical brain slices were cut. 
The slices were placed on a net in recording aCSF saturated with 95 % O2 and 5 % CO2 and 
incubated for 40 min to one hour at 37°C.  The incubation period increased the slices viability 
and was allowing the removal of dead cells on the tissue surface. Afterwards, the slices were 
transferred into the submerged recording chamber (Luigs & Neumann Feinmechanik und 
Elektrotechnik GmbH, Germany), continuously perfused with recording aCSF. All 
electrophysiological experiments were performed at 34°C.      
3.5 Electrophysiological techniques 
Neurons make use of the ion fluxes across their membrane to generate electrical 
signals. They evolved this mechanism to be able to transmit information. An approach to 
identify these electrical signals is to use electrophysiological techniques, which record ion 
fluxes across a cell membrane. They can include the use of extracellular electrodes or 
micropipettes to make a direct contact with the cell of interest. The latter technique can 
include the intracellular recording method, where sharp micropipettes penetrate the cell or 
the patch-clamp method, where the micropipette makes a tight contact with the cell, without 
entering inside the cell (Molleman, 2003).    
3.5.1 Patch-clamp method 
Over the past decades we have acquired plenty of new information due to the patch-
clamp technique which was invented by Neher and Sakmann (1976). This finding made it 
possible to record currents from single ion channels and to understand their contribution to 
the transmission of electrical information in neurons. This method is based on the use of a 
glass pipette with a very small opening (some µm) to make a tight contact with tiny area or 
patch of cellular membrane. After applying negative pressure, the seal is produced by the very 
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high resistance contact between the pipette and the membrane. The resulting small current 
can be measured by an amplifier connected to the pipette. This first conformation is called 
cell-attached patch-clamp recording method (Fig. 9) and enables recordings of single channel 
currents. If the patch membrane is disrupted through suction, the intracellular solution 
Figure 9. Four patch clamp configuration (picture from Purves et al. 
(2004)). 
                                                                                                                                         Materials and Methods  
34 
 
contained in the glass pipette is mixing with the cytoplasm of the cell, allowing measurements 
of electrical potentials and currents of the entire cell. This conformation is called whole-cell 
patch-clamp (Fig. 9). Another variant of the patch-clamp methods includes pulling the glass 
pipette away from the cell, keeping a small piece of membrane attached to the pipette 
without breaking the seal. Overall, these configurations, make the patch clamp technique an 
extremely flexible and resourceful method to study how ion channels function (reviewed by 
Purves et al., 2004) .   
All voltage clamp experiments performed in this study were done using an Axopatch 
200B amplifier (Molecular Devices, Union City, CA, USA), while the current clamp experiments 
(paragraph 3.5.2 and 3.5.3) were performed using a BVC-700A Bridge and VC amplifier (Dagan 
Corporation, Minneapolis MN USA). The amplifier head-stage was mounted on a motorized 
manipulator (LN Unit Junior, Luigs & Neumann Feinmechanik und Elektrotechnik GmbH,  
             Table 5. Brain slices solutions 
aCSF for ClC-2 currents 
 recordings 
Chemicals 
Working solution 
(mM) 
Cutting aCSF NaCl 130.9 
315-325 mOsm/l KCl 2.75 
pH = 7.4 MgSO4*7H2O 1.43 
 NaHCO3 28.82 
 NaH2PO4*H2O 1.1 
 CaCl2 2.5 
 Glucose 11.1 
Recording aCSF NaCl 70 
290 mOsm/l KCl 2.5 
pH = 7.4 MgSO4*7H20 16 
 NaHCO3 26.2 
 CsCl 10 
 Glucose 11 
 TEA 30 
 TTX 0.2*10
-6 
 
ZD 7288 0.05 
aCSF for APs and extracellular 
recordings 
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Cutting aCSF NaCl 125 
305 mOsm/l NaHCO3 25 
pH = 7.4 KCl 2.5 
 MgCl2 *6 H2O 1 
 NaH2PO4 1.25 
 CaCl2 * H2O 1 
 MgCl2 *6 H2O 7 
 Glucose 10 
Recording aCSF NaCl 125 
305 mOsm/l NaHCO3 25 
 KCl 2.5 
 MgCl2 *6 H2O 1 
 NaH2PO4 1.25 
 CaCl2 * H2O 2 
 MgCl2 *6 H2O 1 
 Glucose 10 
Intracellular solution 
for ClC-2 currents recordings 
 
 
290 mOsm/l CsCl 90 
pH = 7.2 Cs-Gluconate 20 
 NaCl 8 
 MgCl2 2 
 HEPES 10 
 EGTA 1 
 QX-314 (Lidocaine) 2 
Intracellular solution 
for APs measurements 
  
290 mOsm/l KCl 5 
pH = 7.2 ATP-Mg 4 
 Phosphocreatine 10 
 GTP-Na 0.3 
 HEPES 10 
 K-Gluconate 125 
 MgCl2*6H2O 2 
 EGTA 10 
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Germany) and fixed next to a Axioskop 2 microscope (Zeiss, Germany), connected to an image 
acquisition B/W CCD-camera, which allowed brain slices visualization on a screen. The 
submerged recording chamber and the microscope were placed on an anti-vibration table for 
patch-clamp setups and a Faraday cage was built around the setup. All metal parts inside the 
cage were grounded using the ground input of the amplifier. The outputs signals of the 
amplifiers were digitalized by a Digidata 1440A digitizer (Axon Instruments, Union City, USA), 
connected to a personal computer, using Clampex 10.2 (Axon Instruments, Union City, USA) 
as acquisition system. Glass pipettes were pulled from borosilicate glass (Science Products 
GmbH) using a Sutter P97 puller (Sutter Instruments). 
3.5.2 Voltage clamp experiments 
Whole-cell voltage clamp technique is a patch-clamp method that controls or clamps 
the voltage (or membrane potential) at a value chosen by the experimenter. This method is 
using a microelectrode to measure the membrane potential and compares it to a set 
command voltage, which is the voltage the experimenter wants to maintain. The 
microelectrode is connected to an amplifier, which injects current into the cell when the 
membrane potential differs from the set command voltage. Therefore, this method is very 
useful to understand how the membrane potential can affect the current flow of different ion 
channels. 
Whole-cell recordings were obtained from neurons of NRT, VB or cortex (layer IV- V) 
of analyzed brain slices. The solutions I have used to record the ClC-2 chloride currents are 
shown in Table 5 (after Rinke et al., 2010). When filled with intracellular solution the 
borosilicate glass microelectrodes had a resistance of 3-5 MΩ. The signals were low-passed 
filtered at 5 kHz and sampled at 20 kHz. Because of the equimolar concentration of Cl- 
between extra- and intracellular solution, the holding voltage was set at 0 mV. ClC-2 chloride 
currents were evoked by stepping the membrane potential from +40 mV to -120 mV for 4 s 
with an additional 1 s step to +40 mV to record tail currents. 
3.5.3 Current clamp experiments 
The current clamp technique is a patch-clamp method that controls or clamps the 
current while measuring the resulting membrane potential. The whole cell current clamp 
recordings in this study were obtained from the NRT. Extracellular and intracellular solutions 
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that were used are summarized in Table 5. For these experiments, the data were low-pass 
filtered at 30 kHz and sampled at 100 kHz. When filled with an intracellular solution the glass 
electrodes had a resistance of 3-5 MΩ. The cells were held at -70 mV. Establishing of the whole 
cell configuration was done in voltage clamp mode. Once this configuration was reached the 
mode was changed into current clamp and the balance bridge compensated. After 5 min of 
incubation time, allowing the exchange of intracellular solution within the cell, hyperpolarizing 
(from -10 to -110 pA for 500 ms) or depolarizing current injections (from -50 to 300 pA for 800 
ms) were applied to measure the input resistance or evoke action potential (AP) trains.   
3.5.4 Extracellular field recordings 
The extracellular field potential measures the extracellular electric potential produced 
by a group of neurons in the proximity of the pipette as a result of synaptic activity. As for the 
patch-clamp experiments, brain slices were positioned in a submerged chamber continuously 
perfused with aCSF and all recordings were performed at 32°C. For these recordings, a four 
channels differential AC amplifier model 1700 (A-M Systems, USA) was used. Extracellular 
signals were recorded simultaneously by three suction electrodes placed on the slice in three 
different areas (NRT, VB, Cortex; Fig. 10). The obtained signals were amplified 10.000 times 
Figure 10. The thalamocortical brain slice showing the three recordings electrodes 
for the extracellular configuration. One electrode is placed in the cortex (layer IV-
V), one in the NRT and one in the VB. Scheme from Nele Dammeier (Department of 
Neurology and Epileptology, Tübingen).  
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and filtered between 0.25 and 1.5 kHz and the resulting trace represented the multiunit AP 
activity.  
3.6 Data analysis 
3.6.1 GABA-induced currents 
The amplitude of the GABA-induced currents was analyzed using Roboocyte2+ (Multi 
Channel Systems, Reutlingen, Germany), Clampfit (pClamp 8.2, Axon Instruments), Microsoft 
Excel (Microsoft, Redmond, WA) and Graphpad Prism software (GraphPad Software, La Jolla, 
CA, USA). The obtained currents were analyzed in two different ways. First, the current 
response of each GABA concentration was normalized to the maximum response evoked by 
the highest GABA concentration. The normalized GABA responses of each cell were fitted to 
the four parameter logistic equation: 
Y = min+
(𝑚𝑎𝑥 −𝑚𝑖𝑛)
1 + 10((LogEC50−X)∗nH
 
with max and min being the maximum and minimum evoked responses and X the 
corresponding GABA concentration. The EC50 value is the concentration of the agonist for 
which half of the maximum response is achieved, while nH is the Hill coefficient, which 
determines the steepness of the dose-response curve. EC50 values were determined for each 
oocyte and the averaged EC50 values for WT and each mutation are shown as mean ± SEM. To 
test the differences in current amplitudes generated in response to 1 mM or 100 µM GABA 
application (for activating GABAA or GABAB receptors, respectively), current responses of 
wildtype and mutant channels recorded on the same day were normalized to the mean value 
of the wild-type channel currents recorded on that day. The ratio between WT and mutation 
obtained in this way was used to calculate the reduction of GABA-induced currents for each 
GABA concentration in the dose-response curve for each mutation in comparison with the WT 
and to draw the predicted dose-response curve. For GABABRs, deactivation time constants 
were derived from a single-exponential fit to the decay phase of Kir 3.1/3.2 GABA mediated 
currents after agonist application. Curve fitting was performed in Clampfit (pClamp 8.2, Axon 
Instruments) and further data analysis were performed with Graphpad Prism software 
(GraphPad Software, La Jolla, CA, USA). 
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3.6.2 GIRK current analysis 
To verify that the oocytes were expressing the injected WT GIRK channels and that 
there was no change in the amplitude of the evoked currents between WT and mutated 
GABBR2 channels in absence of GABA application, potassium currents were recorded either 
in ND96 or in KD40 solution. The latter bath solution was used because a higher potassium 
concentration is necessary to activate the GIRK channels (Ng et al., 1999). The currents were 
induced by 500 ms voltage commands from a holding potential of -10 mV, delivered in 10 mV 
increments from -140 mV to +60 mV. The current amplitudes were measured when they 
reached the steady state and the resulting current-voltage curves were plotted.   
3.6.3 MEA analysis 
Spike and burst analysis were performed off-line by a custom build software, SPANNER 
(RESULT Medical, Düsseldorf, Germany). The analyzed parameters were: number of spike per 
minute, inter-spike interval (ISI), number of bursts per minute, burst duration, inter-burst 
interval (IBI), number of spikes per burst, and kappa (Fig. 11 A). Kappa is a parameter that 
measures the probability of spikes occurring on at least three electrodes at the same time in 
a 10 ms bin. Individually for each channel, the threshold for spike detection was set to 6.2 
standard deviations (SDs) of the average noise amplitude during a 10% "learning phase" at the 
beginning of each measurement. An absolute refractory period of 4 ms and a maximum spike 
width of 2 ms were set on the spike detection algorithm. Burst detection was performed for 
each electrode and the temporal clustering of spikes was compared with a Poisson process of 
independently occurring spikes at the same mean firing rate (null hypothesis). Given the mean 
firing rate (MFR) of each electrode, the probability P (N, Δt|MFR) of finding at least N spikes 
within the time span Δt was calculated using the Poisson distribution. An observed cluster of 
N>3 spikes occurring within Δt was considered as burst, if its Poisson probability P (N, Δt|MFR) 
was below 0.005 (Illes et al., 2009).  
Synchronous network activity was analyzed by population burst (PB) detection using 
custom build Matlab software (RESULT Medical, Düsseldorf, Germany). Spikes from all 
electrodes were aggregated in nonoverlapping 5 ms bins and smoothed by a Gaussian kernel 
with a 100 ms SD to obtain the population firing rate (PFR and Fig. 11 B). 
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Figure 11. MEA Analysis. (A) Recording trace of one channel of a single MEA electrode; several 
electrophysiological parameters may be visualized and analyzed using SPANNER software: inter-burst 
interval (upper trace), inter-spike interval (ISI), burst duration (BD), and spike amplitude (SA) (lower 
trace). Figure adapted from Otto et al. (2009). (B) Representative spike raster plot illustrate spike 
activity on all 60 electrodes. The synchrony of neuronal networks is shown as the population burst (PB) 
shown in blue (upper panel). PFR is shown as the amplitude of total number of spikes in a PB in an 
interval of 100 ms.   
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PB detection was performed in a three-step procedure. First, PB candidate intervals were 
identified as the PFR exceeding the slowly varying 1 s firing rate average. In a second step, the 
PBs from previous described intervals were selected, if their peak firing rate exceeded 3 
standard deviations (SDs) of the recording PFR and 10% of the average of the top five peaks, 
and at least three electrodes participated. Finally, if neighbouring PBs were <200 ms apart, 
they were merged together. The peak firing rate (i.e., the maximum PFR within a PB interval, 
reported in spikes per second) and the number of PBs per minute were analyzed. Additionally 
spikes were collected in 10-ms-wide bins and used for the quantification of firing synchrony 
across pairs of electrodes. Spikes were dichotomized to either zero spikes or at least one spike. 
For two electrodes, they were either active during a time bin or only one electrode active, or 
both were silent. The synchrony was tested by Cohen´s kappa (Woolson & Clarke, 2011).  
3.6.4 Electrophysiological analysis 
For the voltage clamp experiments, the amplitude of the ClC-2 chloride currents was 
calculated as the difference of the inward current at the beginning and the end of the voltage 
step when the steady state was reached. Current-voltage curves were plotted. In this study, I 
was interested in verifying if neurons from NRT, VB or cortex express the ClC-2 channel. 
Therefore the maximal current response was measured and plotted in a scatter dot plot graph. 
 For the current clamp experiments, several parameters were analyzed: the AP 
frequency per each current injection, the input resistance, the AP threshold and the AP width. 
An AP was considered for analysis when the overshoot was exceeding the 0 mV. The AP 
frequency was measured using the automatic event detection setting in Clampfit. A threshold 
was set between the membrane potential (-70 mV) and above 0 mV. All events above the set 
threshold were automatically counted for each current injection. Additionally, the inter-spike 
interval was determined for each AP train for five spikes within the burst and for the last five 
spikes within the tonic firing (Fig. 12). To calculate the input resistance the hyperpolarizing 
current injection steps were applied and potentials´ amplitudes determined for each current 
injection. These amplitudes were plotted against the current injection to obtain a scatter plot 
graph and a trend line was produced. The AP input was measured as the “x” coefficient of the 
trend line. To measure the AP threshold and the AP width, the first AP in the depolarizing 
current injection protocol was used. The AP threshold was defined as the membrane potential 
at which the rate of rise of voltage crossed 50 mV/ms in the first derivative, whereas the AP 
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width was the time occurring between the two peaks in the first derivative of the AP trace 
(Kole and Stuart, 2008 and Fig. 13).  
For the extracellular recordings, the synchrony of the occurring bursts across the three 
areas (NRT, VB and cortex) was calculated. Using Clampfit, the synchronous bursts were 
Figure 12. Interspike interval. The interspike interval was analyzed for the 
first five spikes within the burst and the last spikes within the tonic firing in 
the AP train induced by 300 pA of current injection. 
Figure 13. AP threshold and width. Upper graph: an example of a recorded AP. Lower 
graph: first derivative of the same AP. The AP threshold was calculated as the membrane 
potential at the 50 mV/ms of the first derivative, while the width was calculated as the 
time between the two peeks in the first derivative. 
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automatically counted above a set threshold in all three areas before and after application of 
picrotoxin, which is a non-competitive blocker of GABAARs.  
3.6.5 Statistical analysis 
Data distribution was tested for normally distribution using GraphPad Prism 6 
(GraphPad Software). Groups were compared using one-way ANOVA with Dunnett´s post-hoc 
test for normally distributed data or one-way ANOVA on ranks with Dunn´s post-hoc test for 
not normally distributed data. For some data, two-way ANOVA and Sidak´s multiple 
comparison test was used. For unpaired or paired data sets and normally distributed data, 
Student´s t test was adopted. Mann-Whitney rank-sum test was used for the not normally 
distributed data. All data is presented as mean ± standard error of the mean (SEM). Statistical 
differences are indicated in the figures legend with the following symbols: *p<0.05, **p<0.01, 
***p<0.001.  
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4 Results 
4.1 GABRA3 mutations as a cause of X-linked epileptic 
encephalopathy 
In this study, four missense variants and a microduplication in the GABRA3 gene were 
found in five different families by our collaborators (Fig. 14).  
Genetic analysis and clinical evaluations were done in collaboration with Dorit Lev, Tally 
Lerman-Sagie, Esther Leshinsky-Silver from the Wolfson Medical Center (Holon, Israel), Vera 
M. Kalscheuer from the Max Planck Institute for Molecular Genetics (Berlin, Germany), 
Agnieszka Charzewska from the Department of Medical Genetics (Warsaw, Poland), Pasquale 
Striano and Federico Zara from Institute G. Gaslini (Genova, Italy), Nicola Specchio from IRCCS 
(Rome, Italy), Giuseppe Capovilla from Epilepsy Center, C. Poma Hospital (Mantova, Italy) and 
CeGaT GmbH (Tübingen, Germany).  
In the first family, the affected individuals show a pattern of X-linked inheritance. As 
shown in the pedigree of the family, two males are severely affected with pharmacoresistant 
epileptic encephalopathy and early seizure onset (Fig. 15 A and Table 7). The type of seizures 
Figure 14. Localization of the four GABRA3 identified missense variants. 
(A) GABAAR structure with 23 22 12 subunit. (B) 3 subunit 
representation with four transmembrane domains and localization of the 
four identified variants: three missense variants are localized in the N-
terminal domain and one mutation is located on the extracellular loop 
between transmembrane domain two and three.   
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is very severe with infantile spasm Lennox-Gastaut syndrome for one male and epileptic 
spasm and tonic seizure for his brother. Additionally, they also show severe intellectual 
disability with global developmental delay and late speech development. The other two 
carriers of the mutation, the mother and the sister, show a less severe phenotype with a 
milder developmental delay and some learning disabilities. They have also experienced 
generalized tonic-clonic seizures. One feature of the patients is that they all show common 
dysmorphic features, such as micrognathia and nystagmus. Additionally, the mother and the 
two sons have a cleft palate.  
Table 6. Scores from Prediction software 
Family Mutation PolyPhen-2 SIFT MutationTaster 
1 p.Q242L 0.985 (probably 
damaging) 
0.11  
(tolerated) 
0.999998345510216   
(disease causing) 
2 p.T166M 1.000 (probably 
damaging) 
0.19 
(tolerated) 
0.999980339497156   
(disease causing) 
3 p.T336M 1.000 (probably 
damaging) 
0.12 
(tolerated) 
0.999999448138709  
(disease causing) 
4 p.G47R 1.000 (probably 
damaging) 
0.04  
(damaging) 
0.76938630907083  
(disease causing) 
Figure 15. First identified missense variant p.Q242L in the GABRA3 gene. (A) Family pedigree showing 
the p.Q242L co-segregation. (B) Evolutionary conservation of the amino acid. (C) Sequence reads 
showing the genomic nucleotide change from T (thymidine in red) to A (adenine in green); left: healthy 
individual, middle: female affected, right: male affected. 
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Our collaborators performed whole exome sequencing of the proband (patient III-1), 
which revealed a mutation in GABRA3 gene as the most plausible variant causing the disease 
(c.A725T, p.Q242L). Indeed, all affected individuals, the mother, the two affected sons, and 
daughter carry this mutation, while the healthy father and brother do not (Fig. 15, Table 7). 
The p.Q242 is an evolutionary highly conserved amino acid and the mutation is predicted to 
be deleterious according to prediction software analysis (Table 6). These programs are used 
to predict the possible impact of an amino acid substitution on the structure and function of 
a human protein. By whole exome sequencing of the patients and the healthy brother, our 
collaborators aimed to identify variants which could explain the complex phenotype in this 
family. Since they did not detect any relevant variants in the known genes associated with 
dysmorphic features, it was assumed the p.Q242L in GABRA3 to be the only variant 
responsible for the observed clinical features. Later on, this variant was confirmed in the other 
patients by direct sequencing and excluded in the healthy father, brother, aunts and uncle of 
the proband.  
As a next step, our collaborators wanted to identify if other variants in the GABRA3 
gene or other X-chromosome linked genes were associated with similar clinical features as the 
Figure 16. Second identified missense variant p.T166M in the GABRA3 gene. (A) Family pedigree 
showing the T166M co-segregation. (B) Evolutionary conservation of the amino acid. (C) Sequence 
reads showing the genomic nucleotide change from G (guanine in black) to A (adenine in green); left: 
healthy individual; middle: female affected, right: male affected. 
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ones described in the first family. For that purpose a cohort of 480 individuals showing X-
linked intellectual disability was analyzed by whole X chromosome sequencing. A second 
variant (c.C497T, p.T166M) in the GABRA3 gene was identified in a large family, in which eight 
individuals, four females and four males, are carrying the mutation (Fig. 16 and Table 7). 
Interestingly, some affected individuals displayed similar dysmorphic features with the 
patients from family 1 (e.g. nystagmus, micrognathia, archate palate), but some differences 
as well, such as tall stature (Table 7). The female carriers have experienced incidents of loss of 
consciousness and present some of the dysmorphic features, while two of the males carrying 
the mutation have epilepsy with generalized tonic-clonic seizures. Patients III-6 and III-7, 
although mutation carriers, do not have epilepsy and only III-7 has mild intellectual disability. 
This may be explained by incomplete penetrance. The mutated amino acid, as in the previous 
case, is partially evolutionary conserved and the change in amino acid was found to be 
deleterious according to two prediction programs (Fig. 16 B; Table 6). 
 To investigate the functional effects of both GABRA3 variants and their impact on the 
functionality of the alpha-3 subunit of the GABAA receptor, Xenopus laevis oocytes were used 
as a heterologous expression system and an automated two-microelectrode voltage clamp 
technique. The predicted positions of these mutations are shown in Figure 14 B. First, these 
mutations were introduced in the human isoform of the GABRA3 cDNA. Secondly, to have a 
functional GABAA receptor, cRNAs coding for WT or mutant alpha-3 subunit together with 2 
and 2s subunits in an 1:1:2 ratio were transcribed and co-injected into the oocytes. After 
three days of incubation to allow optimal expression of the GABAA receptors, the GABA-
induced currents were recorded. First, the response to a high GABA concentration of 1 mM 
was examined. This concentration is mimicking the physiological concentration of GABA in the 
synaptic cleft (Roth and Draguhn, 2012) (Fig. 17 C). This first experiment revealed a dramatic 
reduction in the GABA-evoked currents, showing 84 ± 3% less current response in comparison 
to the WT for the Q242L mutation, while the T166M mutation showed a reduction of 76 ± 3%. 
These results clearly indicate a loss of channel function for both variants (Fig. 17 B, C, D). 
Further investigation of GABA-induced currents in response to different GABA concentrations 
revealed a strong decrease in the whole concentration range. 
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Table 7. Main phenotypic characteristics of patients carrying GABRA3 mutations 
Family/ 
mutation 
Individual/ 
Gender 
Seizure 
onset  
(Age) 
Seizure type  
Dysmorphyc 
features 
Development 
Family 1 
c.A725T 
p.Q242L 
II-2/F 21 
generalized tonic-
clonic 
 
cleft palate, 
nystagmus, 
microretrognathia, 
synophiris 
 
mild 
developmental 
delay 
 
c.A725T 
p.Q242L 
III-1/M 3 Infantile spasms 
Lennox-Gastaut 
cleft palate, 
nystagmus, 
micrognathia, 
sloping shoulders, 
short neck 
severe 
intellectual 
disability 
 
c.A725T 
p.Q242L 
III-2/F 7 generalized tonic-
clonic 
 
retrognathia, 
sloping shoulders, 
fine nystagmus 
mild learning 
disabilities 
c.A725T 
p.Q242L 
III-4/M 3 Epileptic spasms 
and tonic 
seizures 
cleft palate, 
micrognathia, 
short neck, 
nystagmus, 
sloping shoulders 
global 
developmental 
delay, walking 
at age 3 y, 
speech 
starting at age 
6 y. Moderate 
intellectual 
disability 
Family 2 
c.C497T 
p.T166M 
II-4/F In 
adulthood 
Incident of loss 
of consciousness 
ND ND 
c.C497T 
p.T166M 
 
II-6/F In 
childhood 
Incident of loss 
of consciousness 
micrognathia, long 
fingers, big low set 
ears, small mouth, 
high stature (172 
cm) 
learning 
difficulties 
c.C497T 
p.T166M 
 
III-3/F absent absent Small mouth, 
micrognathia, 
height 160 cm 
learning 
difficulties 
c.C497T 
p.T166M 
 
III-6/M absent absent ND unaffected 
c.C497T 
p.T166M 
 
III-7/M absent absent elongated skull, 
long neck, narrow 
and narrowly 
spaced palpebral 
fissures, sharply 
ended and long 
nose, arched 
palate, large 
protruding ears, 
mild 
intellectual 
disability, 
learning 
difficulties, 
hyperactivity, 
disturbances 
of visual-
motor 
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sloping shoulders, 
long fingers, 
second and third 
toes – small 
syndactyly 
integration, 
speech defect 
 
c.C497T 
p.T166M 
 
III-10/M 17 Attack of 
unconsciousness; 
generalized 
tonic-clonic 
seizures 
horizontal 
nystagmus, 
micrognathia, 
elongated skull, 
arched palate, 
small mouth, long 
fingers, big low set 
ears, high stature 
(190 cm) 
delayed 
speech; mild 
intellectual 
disability 
 
c.C497T 
p.T166M 
 
III-12/F absent absent Small mouth, 
micrognathia, 
height 160 cm  
Learning 
difficulties 
c.C497T 
p.T166M 
 
III-13/M 12 Attack of 
unconsciousness; 
generalized 
tonic-clonic 
seizures 
horizontal 
nystagmus, 
micrognathia, 
elongated skull, 
arched palate, 
small mouth, long 
fingers, big low set 
ears, high stature 
(182 cm) 
Mild 
intellectual 
disability; 
speech 
starting at 
age 3y 
Family 3 
Intragenic 
GABRA3 
duplication 
I-2/F   no normal 
Intragenic 
GABRA3 
duplication 
II-2/M 3 Generalized 
tonic-clonic 
seizures 
 Borderline 
intellectual 
disability 
Family 4 
c.C1007T 
p.T336M 
 
I-2/F     
c.C1007T 
p.T336M 
 
II-2/F 8 Generalized 
tonic-clonic 
seizures 
  
Family 5 
c.G139A 
p.G47R 
 
II-1/M    Speech 
starting at 
age 6y; 
autism 
spectrum 
disorders 
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The GABA sensitivity was increased only for the Q242L mutation (EC50 of 93 ± 3 and 25 ± 2 µM 
for WT and mutant, respectively), which could however not compensate for the severe loss of 
current amplitudes (see dotted line in Fig. 17 D). 
In parallel to the exome sequencing studies, a diagnostic screening for copy number 
variations (CNV) in patients with severe epilepsy was performed by our collaborators in Italy. 
A new family was identified in which the proband carries a microduplication of the GABRA3 
gene. This duplication was inherited by the healthy mother (Fig. 18 A). The proband suffers 
from severe pharmacoresistant epilepsy with generalized seizures and unlike the previously 
described cases, does not present any dysmorphic features (Table 7, Family 3). Using cultured 
Figure 17.  Functional analysis of GABRA3 mutations associated with severe EE, ID and DF. (A) 
Schematic representation of the 3 subunit and localization of the Q242L and T166M mutations at the 
N-terminal domain. (B) Example of a 322s induced current by 1 mM GABA application recorded in 
Xenopus laevis oocytes (left: WT, center: Q242L, right: T166M); 15 s of GABA application is indicated 
by the line above each current trace. (C) Normalized current response to 1 mM GABA application for 
WT (n = 63), Q242L mutation (n = 29) and T166M mutation (n = 37); ***p< 0.001; one-way ANOVA, 
Dunn´s multiple comparisons test. (D) Dose-response curve for 322s WT (n = 71), Q242L (n = 16) 
and T166M (n = 25) recorded upon application of different GABA concentrations (in µM: 1, 3, 10, 40, 
100, 300 and 1000) and normalized to the maximal response (1000 µM) for each cell. EC50 values were: 
93 ± 3, 25 ± 2 (***p< 0.001; one-way ANOVA, Dunn´s multiple comparisons test) and 104 ± 4 µM for 
the WT, Q242L and T166M, respectively. The predicted dose-response curves, calculated from the 
ratio of the mutant vs. WT response to the application of 1 mM GABA (C) are shown as dashed (Q242L) 
or dotted (T166M) lines. 
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fibroblasts derived from the patient, our collaborators confirmed by RT-PCR that the 
duplications completely disrupts the gene expression. For the proband, it was not possible to 
identify any transcript of the GABRA3 gene after the RT-PCR (II-2, Fig. 18).     
Furthermore, our collaborators searched for additional mutations in GABRA3 gene in 
a cohort of 243 independent families with IGE/GGE syndromes, which were analyzed by whole 
exome sequencing. In one of these families, another mutation could be detected (c.C1007T, 
p.T336M) in a female suffering from IGE with generalized tonic-clonic seizures. Her unaffected 
mother carries the mutation as well, while her father and sister are affected, but they do not 
carry the T336M mutation (Fig. 19 B). Her father has experienced only few generalized tonic-
clonic seizures, while the sister is suffering from childhood absence epilepsy. However, the 
patients do not present any dysmorphic features as the one described for the first two 
families.   
 The fourth identified missense variant (c.G139A, p.G47R) emerged from the same 
cohort of 480 patients with X-linked disability, in which the already described variant T166M 
was found. The proband carrying the mutation does not present any epileptic phenotype, but 
he is affected by an autism spectrum disorder and severe learning disabilities. The second 
affected patient in the family with similar phenotype is his brother, which on the contrary does 
not carry the mutation (Table 7, Family 5 and Fig. 20 B).   
Figure 18. GABRA3 microduplication. (A) Family pedigree revealing the co-segregation of the 
microduplication. (B) RT-PCR showing that reversely transcribed GABRA3 RNA (exons 1-2 and exons 8-
9) from cultured fibroblasts of the proband could not be detected; GAPDH was used as a housekeeping 
gene control. Analysis performed by Prof. Federico Zara (the Laboratory of Neurogenetics and 
Neuroscience, Institute G. Gaslini, Genova, Italy). 
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The last two described mutations, associated with a milder phenotype and no co-
segregation with disease status in the respective pedigree, were also functionally analyzed 
using Xenopus laevis oocytes as a heterologous expression system. The T336M mutation 
revealed a strong loss of channel function when compared to the WT. GABA-evoked currents 
were reduced by 91 ± 2% after application of 1 mM of GABA. This was also confirmed for the 
Figure 19.  Functional analysis of the T336M mutation of the GABRA3 gene found in a patient 
affected with IGE. (A) Schematic representation of the 3 subunit and localization of the 
T336M mutation in the extracellular loop between domain M2 and M3 of the 3 subunit. (B) 
Pedigree of the family revealing the co-segregation of the mutation. (C) Evolutionary 
conservation of the amino acid. (D) Normalized current response to 1 mM GABA application for 
WT (n = 47), T336M mutation (n = 28); ***p< 0.001; Mann-Whitney test. (E) Dose-response 
curves for 322s WT (n = 71) and T336M (n = 14) recorded upon application of different 
GABA concentrations (in µM: 1, 3, 10, 40, 100, 300 and 1000) and normalized to the maximal 
response (1000 µM) for each cell. EC50 values were: 93 ± 3 µM for the WT and 38 ± 3 µM for 
the T336M, respectively; ***p<0.001; Mann-Whitney test. The predicted dose-response curves 
calculated from the ratio of the mutant vs. WT response to application of 1 mM GABA (D) are 
shown as dotted lines.  
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whole GABA concentration range (Fig. 19 D, E). Additionally the GABA sensitivity was 
increased with an EC50 value of 38 ± 4 µM for T336M in comparison with the 93 ± 3 µM for the 
WT GABA induced currents. The G47R showed a significant reduced current response to 1 mM 
GABA application, but the effect was less pronounced than for the other variants. In addition, 
no difference was observed in GABA sensitivity when compared to the WT (Fig. 20 E). 
 
 
               
Figure 20.  Functional analysis of the G47R mutation of the GABRA3 gene found in a patient 
affected with autism spectrum syndrome. (A) Schematic representation of the 3 subunit of the 
GABAAR and localization of the G47R mutation on the N-terminal domain. (B) Pedigree of the 
family revealing the co-segregation of the mutation. (C) Evolutionary conservation of the amino 
acid. (D) Normalized current response to 1 mM GABA application for WT (n = 47) and G47R 
mutation (n = 10); **p< 0.01; t-test. (E) Dose-response curve for 322s WT (n = 71) and G47R (n 
= 19) recorded upon application of different GABA concentrations (in µM: 1, 3, 10, 40, 100, 300 
and 1000) and normalized to the maximal response (1000 µM) for each cell. EC50 values were: 93 
± 3 µM for the WT and 109 ± 6 µM for the G47R, respectively. The predicted dose-response curves, 
calculated from the ratio of the mutant vs. WT response to the application of 1 mM GABA (D) are 
shown as dotted line. 
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4.2 Functional analysis of two de novo mutations identified in patients 
with EE in the GABBR2 gene 
Mutations causing epilepsy have been identified in GABAAR encoding genes, but only 
recently two de novo epilepsy-causing mutations were detected in a metabotropic GABABR 
subtype, GABBR2. These mutations were found by the EuroEPINOMICS-RES (rare epileptic 
syndromes) and Epi4K Consortium by whole exome sequencing of a joint cohort of 356 
proband/parent trios, in which the proband suffers from severe epileptic encephalopathy. 
More specifically, in this case, the patients were affected with infantile spasms or Lennox-
Gastaut syndrome with early seizure onset in the first years of life (Appenzeller et al., 2014). 
Both patients have experienced the first seizure at 1.5 and 2.5 months of age. Additionally, 
they are severely affected by intellectual disability (ID) and impaired language capabilities. The 
patient carrying the p.S695I mutation is affected with infantile spasms (IS), focal dyscognitive 
seizures (FDS) and generalized tonic-clonic seizures (GTCS), while the patient carrying the 
I705N mutation has experienced only IS as seizure type (Table 8). The severity of the mutations 
was analyzed using the prediction program PolyPhen 2. This program assigns a maximum 
value of “1” for the mutations that are predicted as damaging. The mutations analyzed here 
were predicted as “probably damaging” with a score of 0.997 for the S695I mutation and 0.991 
for I705N mutation. 
 
Table 8. Clinical features of affected individuals with de novo GABBR2 mutations from Appenzeller et 
al. (2014) 
 
Mutation Gender/Age Seizure onset (Age) Seizure type  Development  
c.2084 G>T 
p.S695I 
F/3y 1.5 m 
Focal clonic, IS, FDS, 
GTCS 
Profound ID. No 
head control, 
does not sit, no 
speech, reacts to 
music not to 
people 
c.2114T>A 
p.I705A 
M/18y 2.5 m  IS 
Severe ID. 
Autism syndrome 
disorders. No 
speech, walks 
with support 
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Interestingly, both mutations are located in the sixth transmembrane domain of the 
GABABR subunit 2 and the changed amino acids are highly evolutionarily conserved (Fig. 21 
and Fig. 23 C, 24 C). In this study, the mutations were analyzed using the Xenopus laevis oocyte 
expression system. 
 GABAB is a metabotropic receptor and mediates either the activation of the G-protein 
coupled inward rectifying potassium channels (GIRK or Kir) postsynaptically or the inhibition 
of the voltage-gated Ca2+ channels presynaptically. In this study, all electrophysiological 
experiments were performed using co-expressed GIRK1 (Kir3.1) and GIRK2 (Kir3.2) channels 
as reporter channels. Kir channels are heterotetrameric proteins and to be functional Kir 3.1 
was combined with Kir 3.2. Oocytes were injected with cRNAs encoding the WT GABAB subunit 
1 with WT or mutated GABAB subunit 2 to form a GABAB receptor dimers and Kir 3.1 and Kir 
3.2 to be able to assess their function. After RNA injection and three days of incubation, GABA-
mediated potassium currents were recorded using the fully automated Roboocyte2 system 
(MultiChannel Systems, Reutlingen).  
Figure 21. Representation of the GABABR and localization of the identified 
mutations. Both mutations, S695I and I705N, are located in the GABABR subunit 2 
in the sixth transmembrane domain. 
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To confirm that Kir 3.1/3.2 channels are functionally expressed in Xenopus oocytes and 
the current amplitudes are not affected by the mutations, only potassium currents mediated 
by Kir 3.1/3.2 channels were recorded. Currents were evoked using 500 ms lasting pulses to 
potentials ranging from -140 to 60 mV with a 10 mV increment from a holding potential of -
10 mV. It is known that a high extracellular potassium solution is needed to enhance the 
magnitude of Kir 3.1/3.2 currents (Schwenk et al., 2010). For this reason, the initial recordings 
were made using a low potassium solution (ND96 containing 2 mM KCl) as bath solution 
followed by an application of a bath solution containing a higher potassium concentration 
Figure 22. Kir 3.1/3.2 evoked currents. (A) Example of potassium currents mediated by Kir 3.1/3.2 
channels recorded in ND96 solution (left), containing a low potassium concentration (2 mM K+); 
to enhance Kir 3.1/3.2 currents, the oocytes were incubated with KD40 solution, which has a 
higher concentration of potassium (40 mM K+; right). (B) Current-Voltage relations of Kir 3.1/3.2 
currents recorded in oocytes injected either with the WT or with the mutated GABAB2 subunit (WT 
n=23; I705N n=25; S695I n=24). In grey, IV curves are determined from Kir 3.1/3.2 channels 
recorded in ND 96 solution, or in blue in KD 40 solution. 
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(KD40 containing 40 mM of KCl). As shown in Figure 22, the potassium currents mediated by 
Kir 3.1/3.2 were significantly increased when exposed to solution containing a high in 
comparison with a low potassium concentration. No difference was observed in current 
amplitudes recorded from oocytes expressing the GABBR2 mutations or the WT (Fig. 22 B). 
This result confirms that the effect seen in this study was only due to the mutations detected 
in the GABABR.  
Once the functionality of Kir 3.1/3.2 channels was confirmed, the GABA-induced 
currents were recorded. To obtain a stable baseline of potassium currents activity mediated 
Figure 23. Functional analysis of I705N, a de novo mutation found in the GABBR2 receptor. (A) 
Representation of the GABABR and localization of the I705N mutation on the sixth transmembrane 
domain of the GABABR subunit 2. (B) Trio showing the affected boy carrying the heterozygous mutation 
and the unaffected parents (C) Evolutionary conservation of the changed amino acid. (D) Normalized 
current response to 100 µM of GABA application for the WT (n=25) and I705N (n=20). (E) Example of 
a GABA-induced current for WT and I705N to 100 µM GABA concentration. Black line above the 
currents indicates the 60 s of GABA application. (F) Dose response curve for WT (n=14) and I705N (n=6) 
for different GABA concentrations (in µM: 0.001, 0.01, 0.1, 0.3, 1, 3, 10, 100) and calculated by 
normalizing each value to the maximum induced current (100 µM). The EC50 value for the WT was 3.98 
± 0.68 µM while for the mutation it was significantly decreased with a value of 0.48 ± 0.16 µM; *p<0.05 
t-test. Dashed line indicates the predicted dose-response curve for the mutation calculated from the 
ratio of the mutant vs. WT from the 100 µM application.  
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by Kir 3.1/3.2 channels and avoid the currents decline, which occurs in presence of high 
potassium solutions (Vorobiov et al., 1998) and would make it difficult to perform repetitive 
dose-response recordings, oocytes were incubated at least 20 min prior the recordings with 
the high potassium solution. After this incubation period, oocytes were initially exposed to a 
high GABA concentration of 100 µM and GABA-induced potassium currents were recorded for 
WT or mutated channels. The I705N mutation shows no significant difference in comparison 
to the WT. In contrast, the second de novo mutation, S695I, manifests a 75.82 ± 2.8% reduction 
in the current amplitude when compared to the WT, indicating a loss of channel function (Fig. 
23, 24 D and E). 
To further functionally investigate these mutations, a dose-response experiment was 
performed by applying different GABA concentrations (from 1 nM to 100 µM). A significant 
difference in EC50 was found for the I705N mutation when compared to the WT. In fact, the 
EC50 value of the mutation was 0.48 ± 0.16 µM, thus significantly lower than for the WT (3.98 
± 0.68 µM; Fig. 23). This result, together with the fact that the current amplitude was at the 
same level as the WT, clearly indicates a gain of function for this mutation with an increased 
GABA sensitivity. The second mutation expressed in oocytes, S695I, was analyzed in a similar 
manner. First, after a 100 µM GABA application, the normalized current responses to the WT 
current response recorded in the same day showed a significant decrease in amplitude, which 
would imply a loss in channel function (Fig. 24 D). Second, the oocytes were exposed to 
different GABA concentrations and GABA-induced potassium currents were recorded. From 
these values, a dose-response curve was built for each cell by normalizing each current 
response to the maximum current induced by the highest GABA concentration (100 µM) and 
the GABA sensitivity was estimated through EC50 values. As for the previous mutation, the EC50 
value of the S695I mutation was significantly decreased compared to the WT (0.31 ± 0.2 µM 
for S695I and 3.96 ± 0.85 µM for the WT respectively; Fig. 24, F), which indicates an increased 
GABA sensitivity. Moreover, for nanomolar GABA concentrations (100 nM), the current 
response normalized to the mean of the maximal GABA-induced current of the WT recorded 
in the same day, the S695I shows a higher response when compared to the WT. This results 
indicates a gain of function effect at nanomolar GABA concentrations (Fig. 24 G). This 
circumstance is possible when GABABRs are activated by ambient GABA concentrations at 
extrasynaptic sites. Additionally, the time course of GABA deactivation was derived from a 
single-exponential fit from the current traces after 100 µM GABA applications (Fig. 25). This 
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results shows a significantly increased time constant of deactivation for S695I in comparison 
with the WT, indicating that the channels will stay in an open state for a longer time, which 
would be a further evidence for the gain of function effect of this mutation.  
Summarizing, two de novo mutations in the GABBR2 gene, found in patients presenting 
severe epileptic encephalopathy with early seizure onset and critical intellectual disability 
affect two amino acids on the sixth transmembrane domain that are strongly evolutionarily 
Figure 24. Functional analysis of S695I, a de novo mutation found in the GABBR2 receptor. (A) 
Representation of the GABABR and localization of the S695I mutation on the sixth transmembrane 
domain of the GABABR subunit 2. (B) Trio showing the affected girl carrying the heterozygous mutation 
and the unaffected parents. (C) Evolutionary conservation of the changed amino acid. (D) Example of 
a GABA induced current for WT and S695I to 100 µM GABA concentration. Black line above the currents 
indicates the 60 s of GABA application. (E) Normalized current response to 100 µM of GABA application 
for the WT (n=12) and S695I (n=13); ***p<0.001 t-test. (F) Dose-response curve for WT (n=11) and 
S695I (n=9) for different GABA concentrations (in µM: 0.001, 0.01, 0.1, 1, 3, 10, 100) and calculated by 
normalizing each value to the maximum induced current (100 µM). The EC50 value for the WT was 3.96 
± 0.85 µM while for the mutation was significantly decreased with a value of 0.31 ± 0.2 µM; ***p<0.001 
Mann-Whitney test. Dashed line indicates the predicted dose-response curve for the mutation 
calculated from the ratio of the mutant vs. WT from the 100 µM application. (G) Average response of 
100 nM GABA application normalized to the mean of the maximal GABA-induced current of the WT, 
measured in the same day; *p<0.05 t-test.  
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conserved (Fig. 23 A, C; Fig. 24 A, C). The results of the functional analysis performed here 
point out to a gain of function effect for both mutations. The I705N mutations shows an 
increased GABA sensitivity and no change in current amplitude, whereas the S695I shows a 
gain of function effect mainly at lower GABA concentrations, which could influence the 
GABABRs expressed at extrasynaptic sites, if the receptor trafficking is not affected.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 25. Time constant of deactivation for 100 µM GABA 
application. S695I shows an increased time constant of 
deactivation in comparison with the WT. *** p<0.001 One-way 
ANOVA, Dunn´s test; WT (n = 23), I709N (n = 5), S695I (n = 6).  
                                                                                                                                                                        Results 
61 
 
4.3 ClC-2 channel and its role in neuronal excitability  
It is known that the inhibition mediated by GABAA or GABAB receptors is essential for 
a correct function of neuronal networks in the brain as shown by dramatic diseases caused by 
mutations in these proteins (see 4.1 and 4.2).  
In the next part of my thesis, I was interested to understand how inhibition might be 
modulated in a more complex system such as a mouse model, in which the chloride 
homeostasis could be impaired due to the absence of a chloride channel, specifically the ClC-
2 channel. It is believed that this channel can play either a role in assisting GABAARs inhibition 
by Cl- extrusion (Staley, 1994; Staley et al., 1996) or it could drive Cl- ions into the cell, 
therefore being involved directly in neuronal excitability (Ratté & Prescott, 2011). To 
investigate how the ClC-2 channel influences Cl- homeostasis, I have performed 
electrophysiological experiments in thalamocortical brain slices of WT, heterozygous and 
knockout (KO) ClC-2 mice. This type of brain slices was used for several reasons. First, the 
thalamocortical network plays an important role in generation of generalized seizures. 
Second, the thalamocortical system contains the nucleus reticularis thalami (NRT), a thin layer 
of GABAergic inhibitory neurons, in which the expression of the main Cl- extruder in neurons, 
KCC2, is absent. Therefore, the NRT presents an interesting area to study the involvement of 
ClC-2 channels in the oscillatory activity of this network as well as the role of ClC-2 channels 
in neuronal excitability.  
To achieve this goal, I performed patch-clamp experiments to study Cl- currents carried 
by ClC-2 channels in three different areas of the thalamocortical slice: NRT, VB and cortex. 
Also, the excitability of NRT neurons was analyzed by measuring the number of APs generated 
in neurons of KO mice in comparison to those of WT mice. To further understand if the ClC-2 
channel contributes to the function of the thalamocortical network and to investigate if the 
presence of proepileptic drugs may additionally perturb it, extracellular field potential 
recordings were performed and the spontaneous or drug-induced synchronous activity of 
neurons recorded in the three different areas simultaneously. Moreover, to investigate a 
different area of the brain and because ClC-2 channels are highly expressed in the 
hippocampus (Sık et al., 2000), the network activity of ClC-2 hippocampal cultured neurons 
was analyzed in vitro at different time points in presence or absence of blockers of GABAA 
receptor using the microelectrode array (MEA) system.   
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4.3.1 Cl- currents mediated by ClC-2 channels in acute thalamocortical slices 
Cl- currents mediated by ClC-2 channels were recorded from NRT, VB or layer V 
pyramidal neurons of the cortex from P10 to P18 mice. Some of the recordings were obtained 
together with Nele Dammeier (Dept. of Neurology and Epileptology, Tübingen). The currents 
were isolated by blocking sodium, potassium and for some experiments the hyperpolarization 
activated inward currents (Ih). However, the Ih current blocker had no effect on the inward 
recorded currents, confirming that these currents are not Ih mediated, result already shown 
by Rinke and colleagues (2010). Additionally, it was shown that the presence of extracellular 
cesium blocks the Ih activated current (Thoby-Brisson et al., 2000). Moreover, it is known that 
Cl- currents mediated by ClC-2 activate upon hyperpolarization and by a rise in intracellular Cl-
, therefore a high concentration of intracellular Cl- was used (Staley, 1994; Rinke et al., 2010). 
Another characteristic of these currents is that they are slowly activating, reaching the steady 
state only after several seconds. Therefore the currents were elicited by 4 s long pulses from 
+40 mV to -120 mV. As shown in Figure 26 (A, B), the Cl- mediated ClC-2 currents show inward 
Figure 26. ClC-2 currents recordings in thalamus and cortex. (A) Top: Voltage step protocol used to 
elicit Cl- mediated ClC-2 currents; Bottom: current examples from neurons of WT, HET or KO mice, 
recorded in the NRT; (B) current-voltage plots for the currents recorded in the NRT showing inward 
rectification. (C) The maximal current amplitude of WT, HET and KO cells measured in NRT, (D) VB or 
(E) layer V of the cortex. Data presented as mean ± SD of the maximum current amplitude for each 
recorded neuron (NRT: WT n = 9, HET n = 8, KO n = 7; VB: WT n = 3, HET n = 3; Cortex: WT n = 4, HET n 
= 3, KO n = 1), *p<0.05 unpaired t-test. 
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rectification, allowing the Cl- ions to move out of the cell at potentials more negative than the 
equilibrium potential for Cl-, which in this case was 0 mV, because of equimolar Cl- 
concentrations in the extracellular and intracellular solutions. The current amplitudes were 
assessed from the steady state currents recorded at the most negative potential (Fig. 26). As 
shown in Figure 26, it was possible to record Cl- currents mediated by ClC-2 channels in all 
considered areas (NRT, VB and cortex) in neurons from WT and HET mice, meaning that all 
three areas express the ClC-2 channels. However, no difference could be detected between 
currents recorded in the NRT and the cortex of WT and HET animals, while recorded cells from 
the VB from HET animals had slightly reduced current amplitude. As expected, ClC-2 did not 
show any ClC-2 currents in the KO animals. This was verified in the NRT, and the cortex (Fig. 
26 B, C, E). 
4.3.2 Firing properties of inhibitory neurons in the NRT 
After confirming that inhibitory neurons in the NRT express the ClC-2 channel, the aim 
of this study was to characterize the properties of these neurons in ClC-2 KO mice. This thin 
Figure 27. Firing properties of NRT inhibitory neurons. (A) Top: Representative trains of APs recorded 
in neurons of WT (black) or KO (red) animals; bottom: current step protocol used to induce the AP 
trains. (B) AP frequency plot against the current injection. WT (n=13), KO (n=11) *p<0.05 unpaired t-
test; (C) input resistance; WT (n = 13), KO (n = 11). 
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layer of inhibitory neurons is important to maintain the rhythmic activity in the 
thalamocortical system and any alteration of their normal behavior could perturb the function 
of the whole system. In the past years, it was hypothesized that ClC-2 could act in a similar 
way as the KCC2 transporter, assisting Cl- extrusion. Therefore, the absence of KCC2 from the 
NRT would help to isolate the ClC-2 contribution to the excitability of NRT neurons and 
consequently the whole network. For this reason, my first step was to analyze the neuronal 
firing properties in this area. Three different types of inhibitory neurons are found in the NRT: 
(1) typical bursting neurons, which show a fast bursting discharge at the beginning of the AP 
train, (2) atypical bursting neurons, which show a smaller amplitude of burst discharge, and 
(3) tonic firing neurons, which do not show any bursting behavior (Lee et al., 2007). In this 
study, I have functionally analyzed typical bursting neurons, since they are the most abundant 
neurons expressed in the NRT. To this aim, I have used ClC-2 KO mice at post-natal day 14-18 
Figure 28. Interspike interval for 300 pA induced AP train recorded in the NRT neurons. (A) 
Interspike interval for the first five spikes in the train, WT (n = 13), KO (n = 11) **p<0.01 two-way 
ANOVA, Sidak´s multiple comparison test. (B) Interspike interval for the last five spikes in the train 
WT (n = 13), KO (n = 11) **p<0.01, ***p<0.001 two-way ANOVA, Sidak´s multiple comparison 
test. (C) Example of an AP train for WT and KO and protocol used to induce the AP train. Blue 
squares indicate the first and last spikes that were analyzed in the AP train. 
                                                                                                                                                                        Results 
65 
 
(P14-P18) and analyzed the AP frequency for different current injection steps. Inhibitory 
neurons from ClC-2 KO animals showed a lower number of APs in comparison with those from 
WT mice, indicating a reduced inhibition in the thalamocortical network (Fig. 27 A, B). No 
difference was found in the input resistance (Fig 27 C). 
To confirm the decreased firing rate in NRT inhibitory neurons, the interspike interval 
was analyzed. For this purpose, the AP train induced by a 300 pA current injection was 
investigated and the first five spikes within the burst and the last five spikes within the tonic 
firing period analyzed. The interspike interval was significantly increased in neurons from KO 
mice for all five last spikes, while within the burst only the fifth spike showed a longer 
interspike interval (Fig. 28). This result confirms the decrease in inhibition in the NRT inhibitory 
neurons derived from ClC-2 KO mice.  
Additionally, the first AP in the train was analyzed. In Figure 29 A, an example of an AP 
and its first derivative is shown. The AP threshold was calculated as the corresponding voltage 
in the AP, at which the first derivative was reaching 50 mV/ms. The AP width was the 
Figure 29. Action potential properties. (A) Example of the first AP in the train and its 
first derivative. (B) The AP threshold recorded in ClC-2 neurons of KO mice is 
significantly increased compared to the WT. *p<0.05, unpaired t-test. (C) The width 
of the AP from KO mice was significantly broader than the WT. *p<0.05 unpaired t-
test. 
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corresponding time needed in the first derivative to go from peak to peak (Bean, 2007). A 
significant decrease in AP threshold was found in the ClC-2 inhibitory neurons derived from 
KO mice in comparison to the WT ones, meaning that additional current was needed for 
reaching a more depolarized threshold value. Furthermore, the width of the AP measured in 
neurons of ClC-2 KO mice was broader than the one measured in the WT (Fig. 29, B, C).       
4.3.3 Extracellular recordings 
To verify if the reduced activity of inhibitory NRT neurons has any effect on the whole 
thalamocortical network, I have performed extracellular recordings in acute thalamocortical 
brain slices, in which the connections between thalamus and cortex where kept intact. 
Spontaneous activity and synchrony were recorded simultaneously, using three different 
extracellular electrodes, one in the cortex, one in the VB and one in the NRT (Fig. 30 A). The 
thalamocortical slice was exposed to aCSF and the recorded spontaneous synchronous activity 
was not different between genotypes. I then induced synchronous spontaneous activity by 
applying 10 µM picrotoxin, a GABAA receptor blocker. Picrotoxin application induced 
synchronized bursting activities in all three areas with an increased frequency of synchronized 
bursting activity in brain slices derived from ClC-2 KO mice when compared to the WT (Fig. 30 
Figure 30. Extracellular recordings in thalamocortical slices of ClC-2 KO mice. (A) Position of the 
recording electrodes in cortex, NRT and VB. (B) Representative traces of recordings from WT and 
KO and synchronized burst activity across the three areas after application of 10 µM PTX. (C) 
Number of synchronized bursts per minute in WT and KO before and after application of PTX. 
The ClC-2 slices from KO mice showed an increased synchronized activity after PTX application 
when compared with the WT. *p<0.05 unpaired t-test, WT n=7; KO n=9. 
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B, C). This results implies that the absence of ClC-2 channel is not sufficient to induce increased 
spontaneous activity of the analyzed network, but can be considered as susceptibility factor 
for the increased excitability in this model.  
4.3.4 Network analysis using the Microelectrode array (MEA) system 
To further understand how ClC-2 affects the hippocampal neuronal network behavior, 
in vitro experiments were performed using a 60 electrodes MEA system, enabling extracellular 
recordings of spontaneous neuronal activity across all electrodes (Fig. 31). 
The primary hippocampal neuronal cultures were used for several reasons. First, these type 
of neuronal cultures are an established system for the MEA recordings (Hedrich et al., 2014). 
Second, it was shown that ClC-2 channel regulates neuronal excitability in the hippocampus 
(Rinke et al., 2010), therefore it would be interesting to analyze more in detail its role at 
network level. For this purpose, primary hippocampal neuronal cultures derived from ClC-2 
Figure 31. Microelectrode array features. (A) Mea dish containing in the center the 60 
planar electrodes. (B) Enlarged representation of the electrodes. (C) Spontaneous neuronal 
activity across the electrodes. Each grid has a 1 second duration and 100 µV amplitude.    
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KO or WT mice were recorded at different time points: day in vitro (DIV) 11, DIV 18 and DIV 
25. The neuronal network activity could be visualized through spike raster plots (SRPs), in 
which the spikes recorded from each electrode were plotted over time (Fig. 33 B). MEA 
recordings revealed active neurons and partly synchronized already at DIV 11. The population 
burst activity was indicated by spikes occurring at the same time on many electrodes. First, it 
was investigated how the neuronal cultures derived from WT or KO ClC-2 mice change during 
development and if there were any differences between the two genotypes during this period. 
The first developmental difference that could be observed is that the number of population 
bursts of neurons from WT mice decreased significantly after 25 days in vitro, whereas the 
burst duration did not change during this period (Fig. 32). In contrast, neurons from KO mice 
showed a tendency in reducing the number of population bursts already after 18 days in vitro, 
reaching a significant difference after 25 DIV. Furthermore, burst duration in neuronal cultures 
from KO mice significantly increased after DIV 18 and remained constant with further neuronal 
maturation (Fig. 32 B). Another parameter that indicates a higher synchrony when increased 
is the inter-burst interval. As indicated in Figure 32 C, the inter-population burst interval was 
significantly increasing in neuronal networks derived from WT and KO mice by DIV 25.  
 
Figure 32. Developmental differences between WT and KO ClC-2 hippocampal neurons 
recorded on MEA. (A) Number of population bursts is significantly lower for WT DIV 25 in 
comparison with WT DIV 11 and 18 (n = 10); KO DIV 25 is significantly lower than KO DIV 
11 (n =8); *p<0.05, ***p<0.001 one-way ANOVA, Dunn´s post-hoc test. (B) The burst width 
is significantly increasing for the KO DIV 18 and 25 in comparison with DIV 11; *p<0.05 One-
way ANOVA, Tukey´s post-hoc test. (C) Inter population burst interval is significantly 
increasing after 25 DIV for WT and for KO neurons. *p<0.05 One-way ANOVA with Dunn´s 
or Tukey´s post-hoc test.  
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In the next step, network differences between cultures derived from WT and KO were 
compared more in detail. For this purpose, the network activity was analyzed at DIV 18, the 
time when the most striking differences were detected. Indeed, looking at the raw recordings 
and the SRPs, it was obvious that neuronal cultures derived from KO mice were more 
Figure 33. Network activities recorded with MEAs from ClC-2 hippocampal neurons 
derived from WT and KO mice. (A) Representative extracellular traces recorded from four 
channels before and after application of bicuculline. Each grid has a duration of one second 
and an amplitude of 100 µV. (B) SRPs from neurons derived from WT and KO mice before 
and after bicuculline application. 
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synchronized than those from WT. This could be observed by the duration of the bursts, which 
were significantly longer in cultures derived from KO animals compared to WT (Fig. 33 A, B 
and Fig. 34 C).    
Since it was hypothesized that there could be a tight connection between GABAAR and ClC-2 
channels, the recordings were also performed in the presence of bicuculline, a competitive 
antagonist of GABAARs. It is known that application of bicuculline is inducing a more 
synchronized activity of neuronal networks, which may be visible by the organization of single 
spikes in population bursts, an increase in burst duration and increase of inter population 
burst interval (Baltz et al., 2010; Hedrich et al., 2014) (Fig. 33, 34). Spontaneous network 
activity was recorded for two minutes in the control condition followed by two minutes in the 
presence of 10 µM of bicuculline. In figure 33, recordings and spike raster plots (SRPs) of 
network activities of hippocampal neurons from WT and KO ClC-2 animals are shown. As 
expected, bicuculline was inducing an increase in synchronicity, changing all the parameters 
cited above in the WT cultures. However, SRPs and the quantification of the recorded bursts 
(Fig. 33, 34) revealed that in the hippocampal cultures derived from KO mice, the application 
of bicuculline did not lead to further statistically significant changes in the burst duration or in 
any of the parameters mentioned before.   
Figure 34. Quantitative analysis of the network activities from hippocampal neurons derived from 
KO and WT ClC-2 mice, recorded after 18 DIV. (A) The application of bicuculline was decreasing the 
number of population burst in neuronal cultures derived from WT mice. *p<0.05 Wilcoxon paired test. 
(B) Box plots showing an increase in inter-population-burst-interval after the application of bicuculline 
in neuronal cultures derived from WT mice; *p<0.05 paired t-test. (C) Increase in population burst 
width in neurons derived from KO mice in comparison with the WT. Bicuculline was inducing a 
significant increase in population burst width in neurons derived from WT mice. *p<0.05 unpaired t-
test; **p<0.01 paired t-test. WT n=10; KO n=8. 
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5 Discussion  
5.1 Novel GABRA3 mutations as a cause of X-linked EE 
In this thesis, I have investigated four novel mutations identified by our collaborators 
in the 3 subunit of the GABAAR (gene GABRA3). Two of them were found in two families with 
severe epileptic encephalopathy and dysmorphic features. One additional mutation was 
identified in a proband of a family with a milder phenotype, idiopathic/genetic generalized 
epilepsy. A fourth mutation was found in a patient with autism spectrum disorder. Functional 
analysis of the first three mutations revealed a severe loss of channel function (> 75% 
reduction in current amplitudes), whereas for the last mutation, an only 46% in the reduction 
of current amplitude was observed. These results strongly suggest that GABRA3 is a novel 
epilepsy gene, mutations of which cause different phenotypic outcomes from more severe X-
linked EE to milder ones, probably due to incomplete penetrance in some of the families, as 
discussed in further detail below.  
GABAA receptors are ligand-gated anion channels mediating fast synaptic inhibition at 
postsynaptic sites or tonic inhibition at extrasynaptic sites. So far, mutations in four different 
genes (GABRA1, GABRB3, GABRG2 and GABRD) encoding the α1, γ2, β3 and δ subunits of 
GABAA receptors have been associated with different idiopathic epilepsy syndromes including 
childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), and febrile seizures (FS) 
with or without epilepsy including generalized/genetic epilepsy with febrile seizures plus 
(GEFS+). However, it is possible that mutations in GABRA genes can be the cause of more 
severe forms of epilepsy, such as Dravet syndrome (GABRA1, (Carvill et al., 2014)), or Lennox–
Gastaut syndrome (GABRB3, (Allen et al., 2013)). Interestingly, genetic studies have shown 
that many of the most severe EEs are caused by de novo mutations (Claes et al., 2001; 
Weckhuysen et al., 2012; Allen et al., 2013; Suls et al., 2013; Carvill et al., 2014; Lemke et al., 
2014; Nava et al., 2014; Schubert et al., 2014; Weckhuysen & Korff, 2014; Syrbe et al., 2015). 
In contrast, our results implicate the possibility to transfer severe mutations by mildly affected 
female carriers to their severely affected sons.  
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5.1.1 Loss of function mutations in GABRA3 gene and functional consequences 
The GABRA3 gene is located on the X chromosome and encodes for the 3 subunit of 
the GABAAR. The first identified mutation, Q242L, was found in an Israeli family, in which 
females carriers are mildly affected, whereas males are severely affected. This transmission 
goes in line with an X-linked mode of inheritance. The two affected boys suffer from severe 
epileptic encephalopathy with early seizure onset, profound intellectual disability, and 
dysmorphic features. The type of seizure ranges from infantile spasms with Lennox-Gastaut 
syndrome for the first patient to epileptic spasms and tonic seizures for the other one.  
Four males have been identified by our collaborators as carriers of the second GABRA3 
mutation, T166M. Two of them show an epileptic phenotype with intellectual disability, 
whereas of the other two, only one has a mild intellectual disability, and the other one is 
unaffected. Although we would have expected that all males were severely affected, the 
incomplete co-segregation of the mutation with the disease in this family could be explained 
by incomplete penetrance of the mutation. 
 An interesting feature in the families described above is the presence of dysmorphic 
features, which are partially overlapping between the two families, strongly suggesting that 
mutations in GABRA3 gene may be responsible for epilepsy, intellectual disability and 
dysmorphic features. It is not clear how a subunit of GABAA receptors may be linked to 
changes in morphology, but it has been reported that homozygous Gabrb3 knock-out mice 
exhibit a cleft-palate in about half of the cases, and the other half have feeding difficulties as 
neonates (DeLorey et al., 1998). Since 3 subunits can combine with 3 subunits in the brain 
(Studer et al., 2006) loss of function of 3 could affect 3 subunit containing GABAA receptors. 
In line with this study, it has been demonstrated that blockers of GABAARs, such as picrotoxin, 
can induce partial or complete cleft palate in mice, indicating that GABAARs and functional 
GABA signaling are required for palatogenesis (Ding et al., 2004). 
As described above, loss of function mutations in GABAARs have been often observed 
as a cause of epilepsy, but so far no mutation was identified in the GABRA3 gene. It has been 
observed that the α3-subunit of the GABAA receptor has a broad distribution in the rodent 
brain and is specifically expressed in thalamus, being the only alpha subunit expressed in the 
nucleus reticularis thalami (NRT) (Hortnagl et al., 2013). Knock-out mice lacking this subunit 
do not show spontaneous seizures. On the contrary, they show an enhanced intra-NRT 
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inhibition and a reduced susceptibility to pharmacologically induced seizures, probably due to 
a strong compensatory mechanism increasing the expression of a different α-subunit 
(Schofield et al., 2009). However, another mouse study has shown that GABAergic synapses 
are altered in a null mouse of GABRA3 due to the absence of gephyrin clustering of post-
synaptic receptors. This could have consequences in the thalamocortical circuit in the absence 
of compensatory mechanisms (Studer et al., 2006). On the other hand, in epileptic rats, 
immunoreactivity experiments have demonstrated a loss of 3 subunit at the inhibitory 
synapses of NRT neurons, which may indicate a role for 3 in idiopathic generalized epilepsy 
(Liu et al., 2007). Furthermore, an increase in spike and wave discharges, a typical feature of 
absence seizures, was identified in a mouse model in which the benzodiazepine binding site 
of the α3-subunit is disrupted (Christian et al., 2013). This implies that an impaired function of 
the α3-subunit may lead to epileptic seizures, which are not observed in knock-out animals 
because of a possible compensatory mechanism (Schofield et al., 2009).  
IGE/GGE is more common than EE and presumed to have a polygenic background. The 
T336M mutation analyzed in this thesis shows a loss of function effect. However, this mutation 
was only detected in two females whithin the IGE family, the unaffected mother and one of 
the affected daughters, but not in the affected father or sister. The incomplete cosegregation 
of this family, no additional male carrying the mutation, togheter with the fact that the other 
females patients in the other families do not present IGE/GGE syndromes, suggests that other 
genetic variants probably contribute to the patient´s and her relatives´phenotypes.  
The Q242L and T166M associated with more severe phenotype are both located on 
the N-terminal domain of the 3 subunit. Several other mutations identified in the GABAAR 
are located in the N-terminal domain, thus indicating that this domain plays an important role 
for GABAAR function (Macdonald et al., 2010; Hirose, 2014). Indeed, it is known that this part 
is important for the ligand binding to the receptor (Jacob et al., 2008). However, one of the 
potential mechanisms through which these mutations could act, might be a trafficking defect 
or impaired assembly of the subunits, which would lead to reduced number of receptors 
expressed on the membrane surface. This process may lead to increased excitability and may 
explain the seizure activity in the patients. 
Other features, such as the observed nystagmus in the patients carrying Q242L or 
T166M mutations, may be attributed to a specific inhibitory function of GABAA receptor α3-
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subunits in the brainstem or cerebellum. Expression of GABRA3 in these structures has been 
shown using specific antibodies against this subunit (Pirker et al., 2000). 
Functional data for the G47R mutation associated with autistic spectrum disorder does 
not show a severe loss of channel function as for the other characterized mutations. This goes 
in line with the phenotype of the patients, which is not as severe as for the other patients in 
this study. Additionally, the brother of the proband presents the same phenotype without 
carrying the mutation. Probably in this family, the mutation in GABRA3 has only a little 
contribution to the phenotype and other factors have a major contribution to their 
pathological phenotype.  
5.2 GABBR2 de novo mutations as a cause of EE 
Besides GABAARs, GABABRs are the main responsible receptors for inhibition in 
neurons. These metabotropic receptors mediate inhibition in the brain in two ways. First, they 
can interfere with the release of neurotransmitter by blocking Ca2+ channels, with a 
consequence drop in the Ca2+ concentration at presynaptic sites; second they can activate the 
G-protein coupled  inward rectifying potassium (GIRK) channels at postsynaptic sites, which 
results in hyperpolarization (Benarroch, 2012). Another consequence of GABABR signaling 
takes place at dendritic sites, where spillover of GABA by adjacent terminals, may activate 
GABABRs and therefore hyperpolarize the neurons through activation of potassium channels 
resulting in inhibitition of the backpropagation of the APs, which may influence synaptic 
plasticity and AP generation at axon initial segments (Hua A. Han, 2012). 
Although many epilepsy-causing mutations have been detected in different subunits 
of GABAAR, no mutations were found in GABABRs until 2014, when the first two de novo 
mutations were identified in the GABBR2 gene, in two patients suffering from severe EE and, 
more specifically, Infantile Spasms and Lennox-Gastaut Syndrome (Appenzeller et al., 2014).  
Interestingly, both mutated amino acids are highly evolutionarily conserved and 
located on the sixth transmembrane domain, only 10 amino acids from each other. 
Additionally, both patients share a similar severe phenotype with intellectual disability, no 
speech ability and severe seizures that go from infantile spasms to focal dyscognitive and 
generalized tonic-clonic seizures. The functional analysis of the two mutations performed in 
this study showed a gain of function effect for both of them.  
                                                                                                                                                                 Discussion                                                                                                                                                                
75 
 
5.2.1 Gain of function mechanism of de novo I705N and S695I mutations 
The I705N and S695I mutations have a higher GABA sensitivity with significantly lower 
EC50 values in comparison to the WT. Additionally, both mutations have a higher current 
response in the nanomolar GABA concentrations range, which are proposed to be actual 
concentrations for ambient GABA in the brain (Farrant & Nusser, 2005). Furthermore, the 
S695I mutation has a slowing in current deactivation in comparison with the WT, which 
additionally suggests a gain of function effect for this mutation. However at higher GABA 
concentrations, the I705N has no difference in current amplitude when compared with the 
WT, while the current response for S695I is significantly lower than the WT. This would imply 
that these mutations may have a gain of function effect at extrasynaptic sites, where GABABR 
may mediate the tonic inhibition by decreasing the release probability of GABA via 
autoreceptors or glutamate via heteroreceptors (Mapelli et al., 2009). Such an effect would 
only be plausible if the underlining reason for the overall reduction of current amplitudes 
caused by S695I would not be a trafficking defect. Since these results were obtained 
exclusively in oocytes these study did not focus on the trafficking mechanisms.   
 A gain of function of postsynaptic GABABRs can enhance directly the activity of 
extrasynaptic GABAARs. In dentate gyrus granule cells of the hippocampus it was shown that 
baclofen, an agonist of GABABRs, can induce an increase in tonic GABAA-mediated current at 
extrasynaptic sites in subunit containing GABAARs (Tao et al., 2013). This effect is usually 
inhibitory, but in some areas of the brain, for instance the thalamocortical circuit, may develop 
in excitatory. The increase in inhibition in thalamocortical cells can trigger post inhibitory 
rebound bursts of APs, which may turn the whole circuit in a hyperactive and pathological 
state, being therefore a cause of seizure activity (Cope et al., 2010). In line with these studies, 
it was demonstrated that stimulation of GABABRs either by baclofen or by -hydroxybutyrate, 
an endogenous ligand, are able to induce an increase in spike and wave discharges, a typical 
electroencephalogram pattern of absence seizures (Bortolato et al., 2010). Moreover, in the 
hippocampus, baclofen seems to act in a dose-dependent manner. While at high dosage it can 
activate pre- and post-synaptic receptors, at a lower dosage, it acts only on the presynaptic 
transmission. Thus a gain of function via increased GABA sensitivity, observed for both 
mutations, would produce enhanced feedback in the low dosage range via reduced 
presynaptic Ca2+ signalling  and thus a disinhibitory effect with suppression of the synaptic 
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output of some inhibitory neurons, which could promote high frequency oscillatory activity in 
the hippocampus (Dugladze et al., 2013).  
Furthermore, the gain of function effect of the GABABR mutations could be responsible 
for the medical condition observed in the patients. Several studies revealed that activation of 
GABABRs by administration of baclofen to patients resulted in memory loss (Sandyk & Gillman, 
1985). Likewise, in animal models, baclofen has been responsible for augmenting the amnesic 
effect produced by scopolamine in memory-related behavioral tests (Sidel et al., 1988). 
Although the experimental data for S695I indicate a higher sensitivity for lower GABA 
concentrations in the dose-response logarithmic curve, the maximal current amplitude 
induced by the highest GABA concentration has a significantly reduced response when 
compared with the WT. This might indicate a loss of function effect for higher GABA 
concentrations, not found at extrasynaptic sites where these receptors mostly exert their 
function.  
The loss of function of GABABRs has several functional consequences in the brain´s 
physiology. Confirmation of this mechanism emerges from the use of mouse models of 
GABABRs. GABAB KO mice of both GABAB1 and GABAB2 displayed similar phenotypes. GABAB2 
subunit KO mice show spontaneous seizures, hyperalgesia, hyperlocomotor activity and 
severe memory impairment (Gassmann et al., 2004), whereas loss of pre- and post-synaptic 
GABAB responses, epilepsy, hyperalgesia and memory impairment were shown for GABAB1 KO 
mice (Schuler et al., 2001).  
Some years ago, it was demonstrated that GABABRs associate in vivo with a subfamily 
of the KCTD (potassium channel tetramerization domain containing) proteins. These proteins 
interact with the C-terminal domain probably at the GABAB2 subunit. The interaction changes 
the receptor´s kinetics by increasing agonist binding potency and by altering G-protein 
transmission (Schwenk et al., 2010). Since both mutations analyzed in this thesis are located 
on the GABAB2 subunit, they may act through a change in the conformation of the receptor, 
thus affecting the interaction with KCTD proteins. This could potentially represent another 
mechanism relevant for the epileptic phenotype observed in the patients, and further 
functional investigations would be necessary to verify such a hypothesis. 
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5.3 ClC-2 channels and their contribution to neuronal excitability 
In the third part of this thesis, I aimed to investigate the mechanisms of chloride 
homeostasis in a more complex system, such as a mouse model. To this purpose, I used a KO 
mouse model of ClC-2 chloride channel. Several partially controversial studies pointed at the 
potential involvement of the ClC-2 in epilepsy (Niemeyer et al., 2004; Kleefuss-Lie et al., 2009; 
Saint-Martin et al., 2009; Niemeyer et al., 2010; Stolting et al., 2013). However, a recent study 
showed that patients carrying mutations that disrupt the function of the ClC-2 channel are 
affected with leukoencephalopathy, but not epilepsy (Depienne et al., 2013). Nevertheless, 
the function of this channel is not deeply understood, and different studies suggest that ClC-
2 could have distinct, potentially opposite roles in neurons. On the one hand, it would help to 
maintain the hyperpolarized GABA response, by extruding Cl- ions from the cell at potentials 
more negative that its equilibrium potential (Staley, 1994; Staley et al., 1996). On the other 
hand, it was demonstrated that under physiological conditions, ClC-2 may directly contribute 
to neuronal excitability by conducting Cl- into the cell, following the driving force (Ratté & 
Prescott, 2011). 
5.3.1 ClC-2 channel and its expression in the thalamocortical system 
Chloride homeostasis is essential for effective inhibition in the brain. Intracellular 
chloride accumulation in neurons can lead to an excitatory GABAergic response, emphasizing 
the importance of effective chloride extrusion mechanisms. The potassium chloride co-
transporter 2 (KCC2) provides the major chloride extrusion pathway and a similar role has 
been proposed for the chloride channel ClC-2 (Staley, 1994; Ben-Ari, 2002; Rinke et al., 2010). 
Interestingly, the nucleus reticularis of the thalamus (NRT) has a very low expression of the 
KCC2 transporter (Bartho et al., 2004; Sun et al., 2012), indicating the thalamocortical system 
as an ideal area to investigate the ClC-2 contribution to neuronal excitability. Smith et al. 
(1995) have deeply investigated the ClC-2 expression in different areas of the CNS and, in 
addition to the cortex and hippocampus, they identified high expression of the channel in the 
thalamus. Focusing on these results, I aimed to verify whether neurons of the thalamocortical 
system show ClC-2 mediated currents. As expected, ClC-2 currents have been detected in the 
NRT, VB and in the fifth layer of the cortex in neurons derived from WT and heterozygous 
mice, but no currents were detected in neurons derived from KO mice.  
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As demonstrated in other studies (Staley, 1994; Rinke et al., 2010), using a high Cl- 
concentration in the pipette, will result in currents showing inward rectification, thus 
indicating that they are suitable to conduct Cl- ions inward rather than outward when voltages 
are more negative than the Cl- equilibrium potentials. These conditions are sufficient to ensure 
Cl- efflux rather than influx through the ClC-2 channel. Additional support for the importance 
of ClC-2 as a Cl- extruder is derived from an analysis of synaptic connections of fast-spiking 
basket cells in the hippocampus. It was shown that these interneurons are regulated by ClC-2 
channel and during high neuronal activity at specific inhibitory synapses, the voltage-gated Cl− 
channel CIC-2 results to be vital for allowing efflux of accumulated internal Cl− (Földy et al., 
2010). 
5.3.2 Less inhibition in the thalamocortical system 
The thalamocortical system is an important generator of rhythmic activity, such as 
sleep spindles during non-REM sleep, which may become pathologic with 3 Hz spike and wave 
discharges during absence seizures (Huntsman et al., 1999; Avanzini et al., 2000). Because of 
these properties and the lack of expression of KCC2 in these neurons (Bartho et al., 2004; Sun 
et al., 2012), I decided to focus on analyzing the change in excitability of NRT neurons in the 
ClC-2 KO mouse. Moreover, my observations point out that NRT neurons express ClC-2 
channels, by showing ClC-2 currents. 
In addition, the main result of this thesis is that NRT inhibitory neurons, derived from 
KO mice, show a lower firing rate in comparison with the neurons derived from WT mice, 
therefore suggesting a reduction of inhibition in the whole thalamocortical system. This 
finding was unexpected since hitherto the absence of ClC-2 was associated with an increase 
in excitability. In ClC-2 KO pyramidal neurons of the hippocampus, Rinke and colleagues (2010) 
demonstrated that the same current injection elicited more action potentials. Additionally, 
the loss of ClC-2 channel increased the input resistance, confirming the higher excitability of 
the pyramidal neurons. Similarly, loss of ClC-2 resulted in a higher excitability of inhibitory 
neurons of the hippocampus and, therefore, increased inhibition, which might compensate 
for the hyperexcitability of the network and prevent the development of seizures.   
Although many ClC-2 studies were performed on hippocampal cells (Madison et al., 
1986; Földy et al., 2010; Rinke et al., 2010), no investigation was carried out on thalamic 
                                                                                                                                                                 Discussion                                                                                                                                                                
79 
 
neurons. Therefore, it is not clear what a decrease in firing rates in NRT inhibitory neurons 
could represent in the ClC-2 KO mouse and how this would affect the whole network activity. 
Perforated-patch recordings of NRT neurons demonstrated a higher concentration of 
intracellular Cl- than the one usually observed in adult neurons. This results in a much more 
depolarized Cl- reversal potential, which leads GABAARs to behave in a depolarizing manner, 
triggering APs. Responsible of this behavior are the low levels of KCC2 transporter, which 
entails the absence of the main extrusion mechanism of Cl- from neurons (Sun et al., 2012). 
This is an unusual circumstance because GABAergic transmission in the adult brain acts 
through hyperpolarization, due to higher expression of KCC2 (Rivera et al., 1999). A 
depolarized GABAergic activity is usually described in immature cells or in epileptic tissue, 
where depolarizing GABA can trigger APs (Ben-Ari, 2002; Cossart et al., 2005). This raises the 
question about the mechanisms that could be responsible for the lower excitability in NRT 
inhibitory neurons derived from ClC-2 KO mice. In conditions of low KCC2 expression, if ClC-2 
would regulate intracellular Cl- concentration by extrusion mechanisms, an increase ClC-2 
activity would compensate for the absence of KCC2, reducing the disinhibition. On the 
contrary, if ClC-2 would directly regulate the neuronal excitability by leaking Cl- into the 
neurons as previously proposed (Ratté & Prescott, 2011), then ClC-2 would further increase 
the Cl- accumulation in the absence of KCC2. According to the latter hypothesis, if in addition 
to KCC2 also ClC-2 is absent, then the intracellular Cl- would be lower and the ECl- more 
hyperpolarized, resulting in less firing activity in the NRT neurons derived from ClC-2 KO mice, 
which would explain the obtained result in this thesis.     
5.3.3 Contribution of neurons derived from ClC-2 KO mice to the network 
activities 
I further aimed to verify if reduced activity of the NRT inhibitory neurons derived from 
ClC-2 KO mice has any influence on network activity of the thalamocortical circuit. Less intra-
NRT inhibition should lead to higher excitability in the network and possibly to seizures 
(Crunelli & Leresche, 2002; Beenhakker & Huguenard, 2009). However, simultaneous 
recordings of synchronous activity in the thalamocortical brain slices, and more specifically in 
NRT, VB and V layer of the cortex, didn´t show any differences in the synchronized bursting 
behavior of thalamocortical slices from ClC-2 KO mice in comparison with the WT. Indeed, 
studies of ClC-2 deficient mice didn´t identify any spontaneous seizure activity (Bösl et al., 
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2001), which may have resulted from excitatory effects of GABA as proposed in the past (Smith 
et al., 1995; Staley et al., 1996). This observation was later confirmed by Blanz and colleagues 
(2007), who determined the seizure susceptibility of ClC-2 KO mice by exposing them to pro 
convulsants and finding no differences between genotypes. On the other hand, 
electrocorticographic recordings of older ClC-2 KO mice (more than 6 months), revealed 
spontaneous slow spike and wave discharges, and blockage of GABAARs increased even 
further the seizure activity (Cortez et al., 2010). In line with this finding, incubation with 
picrotoxin induced a higher spontaneous and synchronous activity in the thalamocortical brain 
slice even in slices derived from younger ClC-2 KO mice when compared to WT. These 
experiments performed in the thalamocortical system point out that the absence of ClC-2 has 
an effect on the network excitability only in the presence of other perturbating factors, as it 
was found here by blocking GABAARs. This confirms the finding that variations in the ClC-2 
gene alone are not sufficient to produce an epileptic phenotype (Depienne et al., 2013). 
Increasing evidence is suggesting that epilepsy is not only due to the occurrence of single 
mutations, but rather to a co-expression of variants affecting different genes, which may 
contribute to the epileptic phenotype (Kleefuss-Lie et al., 2009; Saint-Martin et al., 2009; 
Klassen et al., 2011). In this picture, ClC-2 would rather act as a susceptibility factor of the 
disease and would have an effect on the neuronal excitability only when expressed in 
combination with mutations in other genes causing the disease or additional stressing factors.  
Whilst no effect could be detected in the extracellular recording of thalamocortical 
slices derived from ClC-2 KO mice, spontaneous network activities of cultured hippocampal 
neurons from these mice, recorded using the microelectrode array (MEA) technique, revealed 
an increase in synchronized activity compared to the WT. The observed changes in some 
parameters, such as an increased burst duration, correspond well to the increase in excitation 
found in pyramidal neurons of the hippocampus in ClC-2 KO mice, although field potentials 
recordings in the same study showed a loss in excitation possibly due to increase of 
feedforward inhibition of a subset of inhibitory interneurons (Rinke et al., 2010). The increased 
excitation in ClC-2 KO MEA recording is possibly due to an impairment in the GABAergic 
transmission, which is not further affected by the block of GABAARs.  
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